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Abstract 
c-Cbl is the major E3 ligase involved in ubiquitination of Epidermal Growth Factor 
Receptor (EGFR). Ubiquitination by c-Cbl plays a critical role in EGFR endocytosis by 
targeting receptors to lysosomal degradation. Its involvement at early internalization steps 
is still debated, also due to the fact that multiple internalization pathways were described. 
Indeed, EGFR ubiquitination is required for non-clathrin mediated endocytosis (NCE), 
while it is not essential for clathrin endocytosis (CME) (1,2). However, c-Cbl might still 
play a crucial function also in CME since, in addition to its role as an E3 ligase, it works 
also as an adaptor, by recruiting several proteins involved in the early phases of this 
process (3).  
Importantly, c-Cbl has been found mutated in different disorders, from 
myeloproliferative disease to Noonan syndrome and non-small cell lung cancer (NSCLC) 
(4). Most of these mutations are located within the Ring finger domain and in the 
regulatory linker region, and are therefore predicted to affect E3 ligase activity. However, 
some mutations map outside this region, suggesting that they might impinge on the adaptor 
function without altering E3 ligase activity. None of these mutations was characterized in 
detail at the mechanistic level. In order to draw a more precise molecular picture of c-Cbl 
activity in EGFR ubiquitination and endocytosis, we investigated the effects of different 
set of cancer-relevant mutations, combining two distinct approaches: 1) RNA interference-
based functional assays and 2) in vitro ubiquitination assays.  
1) First, we characterized the effect of the knockdown (KD) of c-Cbl (and its family 
members) on EGFR ubiquitination and endocytosis in two different cell systems, murine 
fibroblast and HeLa cells. From our data, we confirmed that c-Cbl is essential for NCE, by 
ubiquitinating the EGFR; however, it also plays a role in CME. Importantly, reconstitution 
experiments with RING finger mutants demonstrated that c-Cbl E3 ligase activity is also 
required for CME. Since EGFR ubiquitination is not essential for CME, we hypothesize 
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that this activity is exerted not directly on the receptor but on endocytic adaptors. In 
agreement, Eps15 monoubiquitination is impaired upon c-Cbl KD.  
2) We were able to reconstitute the EGFR ubiquitination reaction in vitro, and now we 
can use this tool to study the molecular details of c-Cbl catalysis.  
 Moreover, in order to dissect c-Cbl adaptor function vs E3 ligase activity, we plan to 
investigate the phenotype of c-Cbl mutations that map outside the E3 ligase domain in 
EGFR internalization and ubiquitination, exploiting both in vivo analyses (through 
reconstitution experiments in cell lines) and in vitro ubiquitination assay. 
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Introduction 
1 The endocytic process 
Endocytosis is a basic cellular process that occurs at the cell surface and involves 
internalization of the plasma membrane (PM) together with its constituent membrane 
proteins and lipids. The endocytic process governs almost all cellular relationships with the 
extracellular environment and intracellular signalling pathways. Over the years, multiple 
cell entry routes have been described (Figure 1). A rough classification is performed on the 
basis of the size of the initial membrane invagination. Particles larger than 500 nm, as 
bacteria or apoptotic cells, are taken up by phagocytosis (5), while fluid uptake occurs by 
macropinocytosis (6). These processes involve large rearrangements of the plasma 
membrane, driven by actin cytoskeleton remodelling and RHO-GTPases activity (7). On 
the contrary, micropinocytosis is characterized by smaller invaginations (<200 nm) and 
comprises both clathrin mediated endocytosis and non-clathrin endocytosis (8). In this 
introduction, we will focus on describing micropinocytic entry routes. 
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Figure 1 Major micropinocytic entry routes in mammalian cells. Multiple pathways of 
endocytosis exist, for example, clathrin-dependent, caveolin-dependent and clathrin- and 
caveolin-independent internalization. Once internalized, cargoes are trafficked into 
endosomes, where they can be either recycled back to the cell surface or sorted into other 
compartments [multivesicular bodies (MVB) and lysosomes] for degradation (9). 
 
 
Table 1 Internalization pathways. The known pathways of internalization are shown 
together with the morphology and the size of the internalizing membrane structure, the 
coat involved, the dependency on dynamin, the involvement of GTPases, the type of 
internalized cargo and the associated molecular machinery. CLIC, clathrin-independent 
carriers; GEEC, GPI-AP enriched early endosomal compartment; RTK, receptor tyrosine 
kinase; GPCR, G protein-coupled receptor; TfR, transferrin receptor; LDLR, low-density 
lipoprotein receptor; DAB2, disabled-2; ARH, autosomal recessive hypercholesterolemia; 
CTxB, cholera toxin B; SV40, simian virus 40; GPI, glycosylphosphatidylinositol; MHC, 
major histocompatibility complex; TGF-bR, transforming growth factor-beta receptor; 
IGF-IR, insulin-like growth factor I receptor; PTRF, polymerase I and transcript release 
factor; SDPR, serum deprivation response; SRBC, SDR-related gene product that binds to 
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c-kinase; MURC, muscle restricted coiled-coil protein; CtBP1, C-terminal binding protein 
1; DAT, dopamine transporter; EAAT2, glial glutamate transporter; AchR, acetylcholine 
receptor (4). 
 
1.1 Clathrin mediated endocytosis 
Among the different cell entry routes, CME has been the most extensively studied (9). 
CME is ubiquitous to all eukaryotic cells and proceeds through a series of well-defined 
morphological intermediates: a clathrin-coated pit (CCP) undergoes progressive 
invagination before scission from the plasma membrane leading to the formation of a 
clathrin-coated vesicle (CCV) (10). As the name suggests, the main component of the 
CCV’s coat is clathrin, which is assembled as a scaffold on the vesicle surface. The final 
structure resembles a sandwich with two outer layers: the inner part of the layer contains 
the cargo while the outer contains clathrin; between these two sheets there is a middle layer 
consisting of different clathrin-adaptor proteins and other regulatory molecules involved in 
the CCV assembly (Figure 2). 
 
Figure 2 Clathrin-dependent endocytosis. Clathrin-dependent endocytosis starts when 
adaptor and clathrin complexes associate with cognate cargo, thus initiating the formation 
of a coated pit. As the pit matures, additional adaptor and scaffold proteins join the pit, 
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providing a structural platform that regulates interactions between the adaptors and the 
other endocytic proteins. Increasing membrane deformation eventually leads to vesicle 
scission, which releases a clathrin-coated vesicle into the cytoplasm. Examples of different 
cargos are given in different colors. Blue and purple cargos, which contain sorting motifs 
that bind to clathrin-associated adaptors, can therefore be incorporated into the forming 
CCP. Yellow cargoes, by contrast, are internalized through an alternative clathrin-
independent pathway that might involve a select subset of CLASP (clathrin-associated 
sorting proteins) adaptors (11). 
 
1.1.1 Clathrin and clathrin coat assembly 
A clathrin coat is three-dimensional (3D) array of triskelia. Each triskelion is composed by 
three clathrin heavy chains (CHCs) with a mass of 170 kDa and three clathrin light chains 
(CLCs) of 25 kDa: the three CHCs provide the structural backbone of the clathrin lattice, 
while the three CLCs seem to regulate the formation and disassembly of the clathrin 
lattice. In vertebrates, two forms of CLCs have been identified, CLCa and CLCb (12). 
CLCs have been shown not to be essential in the process of vesicle formation since their 
concomitant ablation does not affect neither Transferrin Receptor (TfR) nor EGFR 
internalization (13). On the contrary, Ferreira and colleagues demonstrated that CLCa or 
CLCb KD specifically inhibits the uptake of G protein coupled receptors (GPCRs) (14). 
Therefore, CLCs seem to play specific roles in receptor uptake; their involvement in this 
process depends on the receptor being internalized.  
The clathrin heavy chain is an invariant polypeptide made of functionally distinct 
regions (Figure 3). The globular N-terminal domain (NTD) contains the binding sites for 
adaptor proteins, including Adaptor Protein 2 (AP2) and is connected via the ankle region 
to a distal and a proximal leg, linked by a region behaving like a knee. The proximal leg 
portion contains the binding site for the light chain. The hub region consists of the three C-
terminal segments of the heavy chains, belonging to the three monomers implicated in 
triskelion formation. In vitro experiments show that purified clathrin can spontaneously 
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assemble into cages, or in the presence of adaptor proteins, into coats. The first 3D map of 
a clathrin cage, both in presence and in absence of adaptor proteins, was obtained in 1986 
using cryo-EM (electron microscopy) (15). In later years, improvements in EM resolution 
allowed researchers to precisely trace and position the main parts of the triskelion (16).  
 
Figure 3 The architecture of clathrin. (A) Schematic representation of a clathrin 
triskelion, which shows the various domains of CHC with different colours (see the key). 
(B) A clathrin barrel with a single triskelion highlighted in blue (17).  
 
Adaptor and accessory molecules coordinate clathrin nucleation at sites of the 
plasma membrane that will be internalized (18). The nucleation process promotes the 
polymerization of clathrin into curved lattices, by stabilizing the deformation of the 
attached membrane. Clathrin polymerization, together with the concomitant action of other 
proteins, leads to the formation and constriction of the vesicle neck, bringing the 
membranes surrounding the neck in close apposition. The GTPase dynamin forms a helical 
polymer around the constricted neck and mediates the fission of the vesicle from the 
plasma membrane upon GTP (Guanosine 5’-Triphosphate) hydrolysis (19). This results in 
an irreversible release of the CCV into the inner part of the cell; subsequently, the clathrin 
basket is released from the vesicle by the proteins auxilin and hsc70 (heat shock cognate 
70 kDa protein). 
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1.1.2 Clathrin adaptors 
A wide range of adaptors and accessory proteins has been implicated in CCP and CCV 
formation. At least 20 clathrin adaptors have been identified (20). Endocytic adaptor 
proteins vary greatly in size [about 300-3000 amino acids (aa)] and structure, but possess 
similar properties. Most of the clathrin adaptors contain regions that interact with some or 
all the four types of binding partners, namely clathrin, cargo, lipids and accessory proteins 
(11,20). Endocytic adaptors can be divided into two groups: multimeric adaptor proteins 
(for instance AP2) and monomeric or non-classic adaptor proteins, also named CLASPs 
(Figure 4). 
 21 
 
Figure 4 Representation of the major domains and motif organization of human 
adaptors. Multimeric and monomeric adaptor proteins consist of folded domains 
(represented by atomic structures), binding motifs (colored boxes) and relatively 
unstructured regions (represented by thin black curved lines) (11). 
 
 The first adaptor to be identified was the cargo-binding and phospholipid-binding 
heterotetrameric complex AP2. AP2 is the most abundant non-clathrin constituent of 
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purified endocytic CCVs and remains today the prototypical and best characterized 
endocytic adaptor. AP2 is a stable complex of four polypeptide chains: the 100 kDa α-
subunit, the 100 kDa β2-subunit, the 50 kDa µ2 subunit and the 17 kDa σ2 subunit.
 For many years, AP2 was thought to be the only existent cargo-sorting protein. 
However, recently, the discovery that in cells depleted for the AP2 complex some CCPs 
were present at the PM and these were sufficient to induce receptor internalization (13,21) 
challenged this simplicistic view. Indeed, other specific adaptors have been implicated in 
clathrin-coat assembly (9). Some of them have been demonstrated, or proposed, to work in 
concert with AP2 or as its substitute, since they can bind both cargoes and clathrin, such as 
Epsin (22) and β-arrestin (23). 
Adaptor proteins are collectively called CLASPs (20) and are able to bind both 
AP2 and clathrin. CLASPs can be classified on the basis of the motif recognized on the 
cargo. PhosphoTyrosine-binding (PTB) domain-containing CLASPs recognize the 
[FY]XNPX[YF] signal, which is not bound by the µ2 subunit of AP2. The PTB domain is 
able to bind both phosphatidylinositol-4,5-bisphosphate (PIP2) and cargo simultaneously. 
Examples of CLASPs containing PTB domain are Dab2, ARH (autosomal recessive 
hypercholesterolemia) and Numb (24). Other CLASPs, like Epsin family proteins, Eps15 
(Epidermal growth factor receptor substrate 15) and Eps15L1 (Epidermal growth factor 
receptor substrate 15-like 1) recognize ubiquitinated cargoes and bind AP2. For these 
adaptors, cargo selectivity derives from tandemly arrayed ubiquitin-interacting motifs 
(UIMs). Through its NPF motif, epsins associate with the EH domain of Eps15; moreover, 
epsins are able to bind to clathrin (25). These properties of epsins allow the assembly of 
clathrin coat in the absence of AP2.  
Accessory proteins can participate in CME during membrane deformation by 
recruiting other molecules or by performing scaffolding/coordination functions within the 
endocytic process. N-BAR (Bin-amphiphysin-RVS) and BAR domain-containing proteins, 
such as SNX9 (sorting nexin 9) and amphiphysin, can generate and stabilize membrane 
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curvature, bind both clathrin and AP2, and recruit dynamin to the neck of the budding 
vesicle (26,27). Many accessory proteins have been identified, including NECAP, 
intersectin, and stonin, that may play important roles during the endocytic process (18).  
Due to their overlapping binding abilities, CLASP adaptors often play redundant 
roles in CME. Indeed, Eps15 and epsins, are redundantly necessary in EGFR clathrin-
mediated endocytosis (1). Similarly, Eps15 and intersectin are redundantly involved in the 
internalization step of both TfR and EGFR (28). 
To complicate the picture even more, according to cell context, cargo and signal, the 
cell may use the same machinery to trigger different intracellular routes. Indeed, although 
both Eps15 and epsins have traditionally been linked to CME, our lab has recently 
demonstrated that they are also involved in NCE of the EGFR. This latter function is 
exerted through binding of adaptor UIM motifs to cargoes [(1) and paragraph 4.2 of this 
thesis]. 
 
1.2 Dynamin in endocytosis 
Upon the formation of a coated patch of membrane, the generation of an endocytic vesicle 
requires fission of the budded membrane from the parental one. Dynamin, a large GTPase, 
has been implicated in several fission processes in eukaryotic cells (29,30). Dynamin is 
highly conserved among multicellular organisms: the Drosophila and C. elegans 
homologues are 70% and 61% identical to human dynamin, respectively. While both 
Drosophila and C. elegans carry only a single dynamin gene, mammalian cells express 
three dynamin isoforms in a tissue-specific manner. Dynamin-1 is neuron-specific, 
Dynamin-2 is ubiquitously expressed (19) and Dynamin-3 is predominantly expressed in 
testis and, to lesser extent, in neurons. In addition, numerous splice variants exist, which 
suggests that, at least in mammals, these different dynamin family members might exert 
distinct functions, other than receptor-mediated endocytosis. 
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A great variety of endocytic processes including clathrin-dependent and some 
clathrin-independent receptor-mediated endocytosis has been shown to require dynamin 
for the scission process that generates vesicles. Initially, dynamin was identified as 
homologue of the Drosophila shibire gene (31), whose mutations were shown to cause a 
temperature-sensitive paralysis. The first data were obtained from morphological analysis 
of synapses in the shibirets1 mutant, where a reversible loss of synaptic vesicle at 
neuromuscular junctions were observed, implicating dynamin in the endocytic process. 
Moreover, overexpression of a dominant negative mutant of dynamin blocked receptor-
mediated endocytosis in different cells, suggesting a further role in clathrin-dependent 
endocytosis out of the nervous system. A further evidence of the role of dynamin in this 
process is achieved through its localization to CCPs at the plasma membrane (32). 
Dynamin is a large GTPase that contains a Pleckstrin homology (PH) domain, 
which mediates the binding to PIP2; a GTPase effector domain (GED), which can interact 
with the same domain of an adjacent dynamin molecule, by causing oligomerization of the 
proteins and activation of the GTPase activity (33); a C-terminal proline/arginine-rich 
domain (PRD), which allows interactions with SH3 (Src homology 3)-domain containing 
proteins. This wide range of partners enables dynamin to recruit and bind proteins involved 
in coated vesicles formation (Figure 5).  
 
Figure 5 Schematic representation of dynamin domains. Dynamin consists of five 
domains: the GTPase domain, a middle domain, a PH domain, a GED, and a highly basic 
C-terminal PRD (34). 
Besides acting in the scission machinery for the clathrin-dependent pathway, 
dynamin is also implicated in vesicle formation in some clathrin-independent pathways, 
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including caveolar endocytosis (35), Rho-A-dependent IL-2 (Interleukin 2) receptor 
endocytic route (36), APP (amyloid precursor protein) endocytosis in primary neurons (37) 
and a class of macropinocytosis (38) (see Table 1 in section 1). 
Evidence suggests that dynamin is sufficient to promote constriction and generate 
tension for vesicle pinching-off; however other factors are required at the neck of the 
budding vesicle to generate the tension necessary for vesicle budding (39). The mechanism 
by which dynamin is recruited to the endocytic sites at the plasma membrane is poorly 
understood; likely, the GTPase is recruited during clathrin pit assembly, a process in which 
proteins containing N-BAR domain, such as amphiphysin, are involved and can interact 
with dynamin (40). Indeed, in cells, dynamin recruitment to the plasma membrane is 
dramatically reduced by concomitant depletion of endophilin and amphiphysin and 
conversely, depletion of dynamin strongly reduces the recruitment of endophilin (41). 
At high concentration, dynamin forms tetrameric structures, possibly through head-
to-tail interactions between two dynamin dimers (42). During dynamin-dependent 
endocytosis, dynamin tetramers oligomerize in a helical polymer at the neck of the rising 
vesicle. Through its GTPase activity, dynamin then constricts and fuses the two sides of 
the neck, in order to induce budding of the vesicle from the plasma membrane.  
 
1.3 Non-clathrin mediated endocytosis 
Compared to CME, the current understanding of the NCE pathway is much less clear. 
NCE pathways are a heterogeneous group of internalization routes that share insensitivity 
to clathrin depletion and dependency on cholesterol-rich plasma membrane microdomains, 
called rafts. The current classification for non-clathrin mediated pathways rely on the 
requirement of dynamin for vesicle release; thus, clathrin independent pathways are 
divided according to the fact that they use a dynamin-mediated scission mechanism 
(dynamin-dependent) or not (dynamin-independent). A second tier implies the presence of 
coat-like proteins, like caveolins or flotillins, subdividing the pathways in caveolae-
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mediated or flotillin-mediated endocytosis, respectively. A third level of classification is 
based on the involvement of small GTPases; the terminology Cdc42 (cell division control 
protein 42 homolog)-, RhoA- or Arf6 (ADP ribosylation factor)-regulated endocytic 
pathway indicates that modifying the function of these GTPases affects the internalization 
or trafficking of one set of non-clathrin mediated endocytic markers (43,44). 
 
1.3.1 Caveolae-mediated endocytosis  
Caveolae are pits of 60-80 nm diameter formed by the assembly of caveolins (45,46), 
integral membrane proteins that associate directly to membrane cholesterol. They have 
been implicated in NCE, signal transduction, redox signalling, cell adhesion, lipid and 
cholesterol regulation, mechanosensing and even transcription regulation. 
 The structural and regulatory components of caveolae include two protein families: 
caveolins and cavins. There are three mammalian caveolin proteins, caveolin-1 (CAV1), 
caveolin-2 (CAV2) and caveolin-3 (CAV3). Although CAV3 is muscle specific, CAV1 
and CAV2 are present widely in nonmuscle cells, with the exception of neurons and 
leukocytes (47,48). Cells that do not express these proteins lack morphologically evident 
caveolae (49). CAV1 is necessary for caveolar biogenesis (50); on the contrary, loss of 
CAV2 has no apparent effect on caveolae formation in vivo, which suggests that CAV2 
role might be cell specific (51). Recent studies demonstrate that although morphological 
features of caveolae are widely conserved, the functions of the proteins may appear 
different (52). 
In addition to caveolins, four cavins are also critical for the formation of caveolae 
at the plasma membrane (53). Cavins form a multiprotein complex that is recruited to the 
PM by caveolin-1, in a cavin-1 dependent manner (53), where it stabilizes caveolae. 
The caveolar pathway is involved in endocytosis of several ligands such as albumin 
(54), autocrine motile factor (55), tetanus toxin (56), cholera toxin (57), and viruses, like 
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polyoma (58) and SV40 (59).  However, the exact endocytic function of caveolae remains 
object of debate.  
However, several studies have identified common features to all caveolar cell entry 
mechanisms. Indeed, all caveolar cell entry mechanisms depend on dynamin (35), Src 
kinase, PKC (protein kinase C) and actin recruitment (59-61).  
 
1.3.2 CLIC/GEEC pathway 
Glycosyl phopshatidylinositol-anchored proteins (GPI-APs) are membrane proteins that 
lack cytosolic extension and are therefore unable to bind directly cytosolic adaptors. The 
internalization of these proteins is kinetically different from the uptake of transmembrane 
proteins, since they can bypass Rab-5-positive endosomal compartments. The pathway 
involved in GPI-AP internalization delivers cargoes to endosomes termed GPI-AP-
enriched early endosomal compartments (GEECs), which probably result from fusion of 
uncoated tubulovesicular CLICs (clathrin-independent carriers) directly derived from the 
cell surface (62). CLICs/GEECs are selectively enriched for GPI-APs (63), but the 
determinants at this stage at the plasma membrane are not yet clear. However, this sorting 
could be based on lipids, since perturbations in cholesterol and sphingolipids levels affect 
endocytosis through this pathway (61,63).  
 When the CLIC/GEEC pathway is perturbed, endocytosis of GPI-linked proteins 
seems to occur via CME (63). The intracellular destination for cargoes internalized through 
the CLIC/GEEC pathway appears to differ between cell types, including lysosomal and 
pericentriolar recycling compartments (63,64). There is an increasing number of proteins 
internalized through routes that resemble to the GEECs, including cholera toxin (62), 
VacA toxin and SNX9 (65,66). 
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2 Endocytic sorting 
After internalization, cargoes are routed to early endosomes, where distinct trafficking 
paths lead internalized receptors to their fate: either recycling to the plasma membrane or 
lysosomal degradation. Since cargoes destined for degradation are separated from those 
destined for recycling in early endosomes, these structures are considered the first sorting 
station for internalized receptors. 
The specificity of sorting in the early endosome can be defined by: (1) lipid 
composition (67); (2) specific sorting signals on the receptor (68,69); (3) geometric 
constraints in which the membrane-bound components are recycled to the PM, while 
cargoes in the fluid phase are delivered to late endosomes (70).  
Recent evidence has drawn a new picture that reveals early endosomes as a 
morphologically and functionally heterogeneous population, characterized by distinct 
membrane subdomains, which influence the signalling ability and the fate of receptors 
within organelle (71-73). For example, an enrichment in phosphatidylinositol 3-phosphate 
(PI3P) allows the assembly of complexes involving FYVE (Fab1, YOTB, Vac1 and 
EEA1) domain and PX domain-containing proteins (74).  
At the molecular level, two main classes of small GTPases play an essential role for 
sorting cargoes along the endosomal stations: the Rab (75,76) and the Arf families (44). 
These proteins act as molecular switches that can shift between a GTP-bound active state 
and a GDP (Guanosine 5’-Diphosphate)-bound inactive form. The latter is cytosolic, 
whereas the active form is associated with membranes. Rab5 regulates CCV-mediated 
transport from the plasma membrane to the early endosome (76), from which cargoes can 
be recycled back to the PM through either fast Rab4-dependent or a slow Rab8/Rab11-
dependent recycling route (77). Arf6 is involved in an additional recycling pathway, which 
is mainly used by receptors internalized through NCE, such as MHCI (44), although some 
CME-internalized cargoes can also be recycled through this pathway. 
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In other cases cargoes are targeted to degradation in lysosomes through late 
endosomes and multivesicular bodies (MVB) sorting. The transition from early to late 
endosomes is accompanied by the phenomenon called “Rab conversion”, characterized by 
the acquisition of Rab7 at the expense of Rab5 (77). A key signal to enter this pathway is 
cargo ubiquitination, because several proteins that harbour ubiquitin-binding domains 
(UBD) recognize ubiquitinated cargoes and lead them to the degradative route (see also 
chapter 4.1). A central role for the sorting of ubiquitinated cargoes is achieved by ESCRT 
(endosomal sorting complex required for transport) complexes, which act sequentially:  
(1) ESCRT-0 acts at the level of the endosome and is composed of two interacting proteins 
HRS and STAM (Signal Transducing Adaptor Molecule) (78); 
(2) ESCRT-I is a heterotetramer composed by Vps23, Vps28, Vps37, Mvb12 (78) and 
UBAP1 (79) and acts at MVB membrane ; 
(3) ESCRT-II is a heterotetramer consisting of one molecule of Vps22, one molecule of 
Vps36, and two molecules of Vps25. It also acts at MVB membrane (78); 
(4) ESCRT-III, unlike other ESCRTs, which are stable complexes, is a dynamic polymer 
of ESCRT-III proteins whose stoichiometry is not clearly defined. It also acts at the MVB 
membrane (78). 
ESCRT-I, ESCRT-II and ESCRT-III complexes are necessary for the formation of 
intraluminal vesicles (ILVs) of MVBs, accomplished by involution of the liming 
membrane. Moreover, they are involved in the recruitment of the enzymes that 
deubiquitinate receptors before their sorting into ILVs.  
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3 Endocytosis and signalling 
Endocytosis is a major mechanism of long-termed attenuation; however recent evidence 
has shown that endocytosis has a wider impact on signalling, by enabling cells to adopt 
several strategies for the regulation of signal propagation and duration. Endocytosis has 
recently been described as a key player that fine-tunes a diverse array of biological output 
in response to stimuli, thus defining signal specificity. 
  
3.1 Regulation of signalling at the plasma membrane 
Ligand-induced internalization of signalling receptors is an important mechanism able to 
negatively regulate signalling from the cell surface. Receptor endocytosis can attenuate the 
duration or strength of signalling from the plasma membrane by physically decreasing the 
number of cell surface receptors accessible to the ligand (Figure 6). However, in some 
cases, a reduction in the concentration of surface receptors does not result in attenuation of 
the maximal signalling response that can be elicited by a ligand, but it shifts the dose 
response, so that higher concentration of the ligands are required to induce a response of 
the same magnitude. For instance this mechanism is functional during chemotaxis in 
response to soluble ligands. Several plasma membrane receptors, such as RTKs and 
GPCRs, function as motogenic sensors that are able to respond to gradients of chemotactic 
factors that drive cell migration (80). Besides the directional moving, cells have also to be 
able to stop at their target sites, where there is the highest concentration of chemotactic 
factors (81). For example, mammary carcinoma cell lines migrate in response to a gradient 
of EGF (Epidermal Growth Factor). At the beginning of this process, EGFR is uniformly 
distributed all over the cell surface; then, EGF binding at the fore end of the cell causes 
ligand sequestration. The subsequent internalization and degradation of the ligand-receptor 
complex renders the cells progressively less sensitive to the chemotactic stimulus, until 
they stop at their target sites (82) where the concentration is higher. These kinds of 
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regulatory mechanisms are very common in nature and are critical to organize migration 
throughout development.  
  
Figure 6 Endocytosis regulates signalling from the plasma membrane. Schematic 
picture of signal attenuation. Ligand-induced activation of RTKs or GPCRs promotes 
signalling from the plasma membrane through the receptor-mediated recruitment of 
signalling effectors to phosphorylated RTKs, or the activation of G proteins associated 
with GPCRs when the Gα subunit is bound to GTP (step 1). GPCR signalling can be 
mediated both by the GTP-bound Gα subunit (as depicted) and by the Gβ–Gγ subcomplex. 
The following receptor recruitment into coated pits (step 2) and clathrin-dependent 
endocytosis (step 3) attenuate signalling by separating the receptors from plasma 
membrane-delimited substrates and/or mediators. Some receptors traffic to lysosomes, 
which results in their downregulation by proteolysis and further signalling attenuation (step 
4) (83). 
 
Signalling can also be modulated through the regulation of ligand accessibility to 
the receptor. An example of this kind of regulation is seen in Notch receptor signalling. 
The direct binding of DSL ligands (DELTA, SERRATE, LAG-2) – which are anchored at 
the PM of a signal-sending cell – to the receptor Notch – localized at the membrane of a 
signal-receiving cell – is necessary to induce Notch signalling. Upon ligand binding, the 
Notch receptor undergoes two proteolytic cleavage events: the first cleavage is catalyzed 
by ADAM (A Disintegrin And Metalloproteinase)-family metalloproteases, whereas the 
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second is mediated by γ-secretase. The second cleavage occurs in the transmembrane 
region of Notch and releases the soluble Notch intracellular domain (NICD), which then 
translocates to the nucleus and promotes transcription of target genes (84). In order to 
activate signalling, endocytosis seems to be necessary both in the signal-receiving and in 
the signal-sending cell. In the signal-receiving cell, endocytosis of Notch is required for its 
activation, since the γ-secretase cleavage probably occurs in endosomes. Interestingly, 
Notch activation in the signal receiving-cell also requires endocytosis to occur in the 
signal-sending cell. At least in the case of Delta ligand, internalization seems to be 
required to “activate” the ligand (85). Studies from flies and frogs (86,87) identified Delta 
as a substrate for the E3 ligase Neur. Indeed, Neur localizes to the plasma membrane, 
physically interacts with Delta, and promotes Delta ubiquitination. The addition of 
ubiquitin (Ub) moiety to Delta stimulates its removal from the cell surface via endocytosis 
and correlates with a loss in Delta protein. Endocytosis and recycling of Delta to specific 
restricted regions of the PM are probably necessary to maintain an enough high local 
concentration of ligand to induce robust Notch activation, as indicated also by recent 
evidence in Drosophila (88). As found for Neur, Mib mediated ubiquitination promotes 
ligand endocytosis, although this does not appear to promote ligand degradation as 
reported for Neur (86,87). These findings are consistent with a role for Mib ubiquitination 
in generating ligand signalling potential by promoting ligand endocytosis rather than 
regulating levels of ligand for Notch activation. 
Spatial and temporal regulation of signalling can be also achieved through a 
differential distribution of signalling effectors between the plasma membrane and the 
endosomal compartment [e.g. signalling molecules, specific phospholipids (4)]. Receptors 
removal from the plasma membrane, through endocytosis, additionally extinguishes 
signals that depend specifically on plasma membrane molecules. For example, GPCR 
signalling through PM-potassium channels requires that receptors and G proteins are 
present in the same membrane (89); similarly PLCγ1 (phospholipase Cγ1) and PI3K 
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(phosphoinositide 3-kinase) signalling by EGFR is inhibited by receptor internalization 
due to the lack of their lipid substrate, PIP2, in endosomes (90). 
 
3.2 Regulation of signalling by internalization routes 
The biological output of a specific signal depends not only on internalization of receptor 
and ligands into endosomal organelles, but also on the endocytic route through which 
receptors reach the different compartments. Different signalling receptors, including 
RTKs, GPCRs, TGFβR, Notch and Wnt undergo both CME and NCE and the relative 
partitioning in the two endocytic routes defines the final output in terms of sustaining or 
attenuating signalling (Figure 7). TGFβR, for instance, can be internalized both by CME 
and NCE. Proteins of the TGFβ superfamily signal through the transmembrane Ser-Thr 
kinase TGFβR type I (TβRI) and type II (TβRII), whose dimerization results in the 
activation of type I receptor. Consequent phosphorylation of the receptor-regulated Smads 
causes SARA (SMAD anchor for receptor activation) binding to the receptors. SARA 
protein contains a FYVE domain, which also binds to membranes through specific 
interactions with PI3P. Receptors that are internalized through the clathrin pathway sustain 
signalling; on the contrary, receptors that enter the cell through NCE associate with Smad7 
and the E3 Ub ligase SMURF, which results in receptor ubiquitination and subsequent 
degradation (91). A similar scenario is described for internalization and signalling of 
EGFR [(92) and see also section 7].  
While in the case of TGFβR and EGFR, CME leads to signalling and NCE to 
degradation, other cargoes, such as Wnt3a-activated low-density receptor-related protein 6 
(LRP6), exploit the two internalization pathways in the opposite manner. In presence of 
Wnt3a, LPR6 is phosphorylated and internalized into a caveolin-positive vesicular 
compartment, where it stabilizes β-catenin and transduces the signal via the CK1γ kinase. 
However, when LRP6 binds the Wnt3a antagonist Dkk (Dickkopf), the caveolin pathway 
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is displaced by the clathrin pathway. In the absence of the kinase, signal transduction does 
not occur, and this leads to enhanced β-catenin degradation (93).  
 
 
Figure 7 Signalling regulation through different entry routes. Endocytic vesicles 
derived from both clathrin-dependent and clathrin-independent endocytosis fuse with early 
endosomes. Endosomal trafficking is controlled by several Rab proteins - small GTP-
binding proteins of the Ras superfamily. Each GTP-bound Rab protein resides in a 
particular type of endosome and functions by recruiting specific effector proteins. 
Following their internalization into early RAB5-containing endosomes, receptors can 
rapidly recycle back to the plasma membrane by a RAB4-dependent mechanism, traffic to 
the recycling compartment that contains RAB11A or remain in endosomes, which mature 
into MVB and late endosomes. Early-to-late endosome maturation involves the acquisition 
of RAB7 and the removal of endosomal components that are necessary for recycling. In 
the MVBs, cargo destined for degradation is incorporated into ILVs. Fusion of late 
endosomes and MVBs with lysosomes carrying proteolytic enzymes results in cargo 
degradation (83).  
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3.3 Regulation of signalling by endosomal compartimentalization 
A large body of evidence shows that signalling is not restricted to the plasma membrane. 
On the contrary, as internalization goes further, activated transmembrane molecules get 
confined and enriched within endosomal organelles. Endosomes have many unique 
features that give them the ability to act as signalling platform during signal transduction 
from various receptors. The fact that endosomes exist in functional states has led to the 
concept of the “signalling endosome” (83,94). This model has focused on early endosomes 
in the first place, but recently, new evidence shows that also the other endocytic 
compartment performs distinct signalling roles. Endosomes are characterized by: (1) a 
small volume that favors ligand-receptor binding and the maintenance of receptor activity; 
(2) slow sorting mechanisms, as activated receptors have relatively longer resident times in 
endosomes, compared to the PM; (3) ability to use microtubular transport to move for long 
distances and towards the nucleus; (4) enrichment in particular lipids or proteins (such as 
PI3P and small GTPases), which contribute to the scaffold promoting-microenvironment, 
by recruiting proteins containing FYVE and PX domain (74); and (5) microenvironment 
characterized by low pH, especially in late endosomes, which favours specific reactions, 
such as proteolysis of signalling molecules. Endosomal signalling can mainly occur in two 
ways: by sustaining signals originating from the plasma membrane, or by assembling 
specific signal complexes that are not allowed at the PM (94,95). 
In systems where activated receptors are rapidly endocytosed, the ability of a 
receptor to signal after its internalization is crucial to ensure the sufficient duration and 
intensity of signalling. To this purpose, it is important that receptors remain active in the 
endosomes. Several RTKs and their ligands, including the complex EGF-EGFR, remain 
bound and active once internalized in endosomes and throughout the endosomal trafficking 
(96). Moreover, evidence that EGFR continues to be active after being internalized is given 
by the fact that all the components of the ERK (extracellular signal regulated kinase) – 
MAPK (mitogen-activated protein kinase) activation cascade can be detected in 
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endosomes (96). An additional line of evidence is provided by experiments with siRNAs 
(small interfering RNAs) targeting proteins involved in internalization, which show that 
the endocytic process is required for ERK activation by several kinases (92,97). 
Furthermore, endosomal-specific proteins that are important to sustain signalling have 
been identified: for instance, P18 works as an anchor for an ERK-activating scaffold and is 
required for the maximal amplitude of ERK1/2 phosphorylation (98). A similar mechanism 
has been described for GPCR signalling, where β-arrestin acts as a specific scaffold stably 
anchoring ERK1/2 to the endosome. It has also been proposed that β-arrestin promotes 
signalling towards cytosolic rather than nuclear ERK substates (99).  
As previously described, endosomes can support signalling processes that cannot 
occur, or occur with low efficiency, at the plasma membrane, by acting as obligatory 
intermediate signalling stations between the PM and the nucleus. An example is provided 
by the endosomal machinery involved in the propagation of signalling from 
TGFβ receptor. Internalization of TGFβ receptor allows the interaction between the type I 
and the FYVE domain containing adaptor SARA in early endosomes (100). The 
interaction of SARA with SMAD2 allows the phosphorylation of SMAD2 by the receptor 
in endosomes. Then, SMAD2 dissociates in order to interact with SMAD4 and the 
complex translocates into the nucleus, by regulating gene transcription. Also the protein 
endofin contains FYVE domain, potentiating TGFβ signalling from endosomes (101).  
Another example of endosome-specific signal is provided by GPCR signalling, in 
which the activation of Ste2 results in the activation of the trimeric G protein complex 
through the release of the β and γ subunit from the GTP-binding α1 subunit (Gpa1). Gpa1 
translocates to the endosomal compartment and binds Vps15. In these stations, Gpa1 can 
be subsequently activated by the guanine nucleotide exchange factor Arr4, leading to the 
activation of the kinase Vps34 that converts phosphatidylinositol to phosphatidylinositol 3-
phosphate. Increasing concentration of PI3P promotes the recruitment of Bem1 (Bud 
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emergence protein 1) and other proteins involved in the potentiation of MAPKs and Cdc42 
signalling cascades (83). 
A third example that sustains the endosomal hypothesis is provided by RTK 
signalling. Indeed, it has been proposed that endosomes containing EGFR, Rab5 and the 
Rab5 effectors APPL1 (adaptor protein, phosphotyrosine interaction, PH domain and 
leucine zipper-containing 1) and APPL2 can function as signalling platform (72). APPL-
containing endosomes are early endosomes that contain Rab5 but not EEA1 (Early 
Endosome Antigen 1); it seems that APPL proteins compete with EEA1 to bind to the 
active Rab5 (73). Activation of the kinase VPS34 converts phosphatidylinositol to 
phosphatidylinositol 3-phosphate, leading to accumulation of EEA1 and concomitant 
dissociation of APPLs. In HeLa cells, APPL-containing endosomes appear to be necessary 
for ERK1 and ERK2 activation and Akt signalling to GSK3β and mTOR (73). 
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4 The Ubiquitin System 
The posttranslational modification of signalling receptors by the covalent attachment of 
one or more ubiquitin moieties has emerged as one of the major mechanism regulating 
receptor trafficking, sorting and downregulation.  
Ubiquitin is a conserved protein of 76 amino acids that is covalently conjugated to 
several proteins by the formation of an isopeptide bond between its C (carboxy)-terminal 
glycine carboxy group and the ε-amino group of a lysine (lys) residue on the substrate 
proteins (102). Ubiquitination is the result of three sequential enzymatic reactions 
catalyzed by a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and 
a ubiquitin ligase (E3) (102) (Figure 8). The first step catalyzed by the E1 consists of ATP-
dependent activation of the carboxyl terminus of ubiquitin and its conjugation to an active 
site of cysteine residue in the E1. In the second step, ubiquitin is then transferred to a 
similar cysteine residue in the active site of the E2, also through a thiol-ester linkage. The 
final step is accomplished by the E3 ligase and results in the formation of an isopeptide 
bond with the ε-amino group of a lysine residue in the substrate (103). There are two main 
families of E3 ligases: HECT (Homologous to the E6-AP Carboxyl Terminus)-type and 
RING (Really Interesting Gene)-type (Figure 8). The HECT family, which includes Nedd4 
(neural precursor cell expressed developmentally downregulated protein-4) family ligases, 
catalyzes the transfer of ubiquitin from the E2 to its catalytic cysteine through the 
formation of a thiol-ester bond and then to the substrate. Unlike the HECT domain, the 
RING finger domain does not possess the catalytic cysteine and does not form any 
catalytic intermediate with ubiquitin. Instead, the RING finger serves as a scaffold that 
brings E2 and substrate together, and different studies suggest that RING finger domains 
can also allosterically activate E2s (104). Members of the RING-type family can function 
as monomers, dimers or multi-subunit complexes. Dimerization generally occurs through 
the RING finger domain or surrounding regions and can result in homodimers, e.g. RNF4 
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(ring finger protein 4), and TRAF2 (TNF receptor- associated factor 2) (105,106) or 
heterodimers, e.g. BRCA1 (breast cancer 1) and BARD1 (BRCA1-associated RING 
domain 1) (107). Recent studies have demonstrated that dimeric E3 RING finger ligases 
are not only inert scaffolds that bring E2-loaded ubiquitin and the substrate in close 
proximity, but they also actively facilitate the transfer of ubiquitin (108). 
The ubiquitin modification can be reversed by the action of deubiquitinating 
enzymes (DUBs) that recycle ubiquitin to the cytoplasmic pool (109). Thus, ubiquitination 
is a highly reversible process. 
 
Figure 8 Schematic representation of the ubiquitination process. A hierarchical set of 
three types of enzyme is required for substrate ubiquitination: ubiquitin-activating (E1), 
ubiquitin-conjugating (E2) and ubiquitin-ligase (E3) enzymes. The two major classes of E3 
ligases are shown (110). 
 
Ubiquitin can be itself modified on any of its seven lysine residues (lys6, lys11, 
lys27, lys29, lys33, lys48, lys63), leading to the formation of polyubiquitin chains that 
show different structures and features depending on how the chains are assembled (111). 
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Moreover, chains that contain multiple Ub moieties can be formed by either homotypic or 
heterotypic linkages (111). 
The different types of substrate ubiquitination include the conjugation of one 
ubiquitin moiety (monoubiquitination), several single Ub moieties per substrate (multiple 
monoubiquitination), or substrate polyubiquitination when ubiquitin chains are linked 
(Figure 9). Lys48-linked polyubiquitination is composed by a minimal unit of four 
ubiquitin moieties and targets proteins to proteasomal degradation. In contrast, lys63 
chains and monoUb mediate nonproteasomal cellular functions (112): they are implicated 
in the regulation of endocytosis and targeting for lysosomal degradation, besides to the 
control of histone activity, DNA repair and virus budding (103,113). In yeast, lys63 chains 
are required for maximal internalization rates of a subset of nutrient permeases (114,115). 
A similar behaviour has been observed in mammalian cells. MHC class I molecules (116) 
and nerve growth factor (NGF) receptor (117) require lys63 chains for internalization, 
while EGFR is modified by both monoUb and lys63. Lys11-linked chains bind 
proteasomal receptors and trigger degradation of cell cycle regulators during mitosis (118). 
In human cells, lys11 linkages accumulate dramatically upon activation of the APC/C, and 
inhibition of lys11-linked chain formation stabilizes APC/C-substrates and leads to cell 
cycle arrest (118). Other chain types are involved in proteasomal degradation less 
frequently. Lys29-linked chains contribute to substrate turnover in the ubiquitin-fusion-
degradation pathway (119), and in a few cases, lys63-linked or mixed chains trigger 
degradation (120). In conclusion, lys11-, lys29-, lys48-, and lys63-linked chains might all 
mediate proteasomal degradation, a diversity in targeting signals that is reflected by the 
plasticity in substrate recognition by proteasomal subunits. Much less is known about the 
precise function of chains that are linked through lys6, lys27 and lys33 (103,121). 
 41 
 
Figure 9 Schematic representation of the different ubiquitin modifications and their 
functional roles. The question mark indicates that the functions of branched chains are 
mostly unknown (110).  
 
Ubiquitin modifications on the target proteins are recognized by an array of UBDs 
that bind noncovalently to ubiquitin. At least nine specialized UBD have been identified so 
far (122): ubiquitin associated (UBA) domain; UIM; ubiquitin E2 variant (UEV); Cuel-
homologues (CUE); poly-Ub-associated zinc-finger (PAZ); Gram-like Ub-binding in 
Eap45 (GLUE); Np14 zinc-finger (NZF); Vps27, Hrs, STAM (VHS) and GGA (Golgi-
localized, gamma-ear-containing, Arf-binding protein) and TOM1 (GAT). These different 
UBDs might have evolved to allow a great variety of proteins to interact with ubiquitin or 
ubiquitinated proteins during several cellular processes. The formation of complex 
ubiquitin-UBD interaction networks controls several cellular processes (123), for instance 
many endocytic proteins acting at different steps of the endocytic cascade possess UBD, 
which are crucial to regulate receptor trafficking (see next chapter 4.1). 
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4.1 Ubiquitin in endocytosis 
Ubiquitin-mediated endocytosis was first identified in studies using the yeast 
Saccharomyces cerevisiae that demonstrated that internalization of several PM cargoes, 
including Ste6 (124) and Ste2 (114,125), required ubiquitin. Indeed, for many yeast 
cargoes, Ub modifications are both necessary and sufficient for endocytosis (125) although 
Ub-independent endocytosis of cargoes has also been described (126). The general 
consensus is that Ub-mediated endocytosis is the preponderant mechanism for 
internalization of most cargoes studied in yeast. However, in mammalian cells, the role of 
ubiquitin in endocytosis is somewhat more complicated. In the case of ion channels, 
ubiquitination is essential for their internalization (83). For many endocytic cargoes in 
mammalian cells, including RTKs and GPCRs, ubiquitination appears to be sufficient for 
endocytic uptake (1,127). Importantly, although many of these cargoes exhibit ligand-
dependent ubiquitin modification, they also possess Ub-independent endocytosis. Thus, in 
mammalian cells, ubiquitination is often sufficient, but not required, for internalization. 
This is indicative of multiple redundant, yet distinct, mechanisms of endocytosis (128).  
Despite a clear regulatory role of ubiquitination in targeting cargoes for 
endocytosis, it has been difficult to establish an exclusive role in this process for several 
reasons. First, in mammalian cells different kinds of endocytosis exist, which often act in 
parallel in internalization of specific cargoes. These internalization pathways might have 
distinct sorting determinants and might depend or not on receptor ubiquitination. One 
critical example in this sense is represented by the EGFR, as will be illustrated in detail in 
the section 7. Secondly, the endocytic interactors contain many UBDs, which may act 
redundantly or serve as avidity sensors to increase the efficiency of sorting for endocytosis. 
Moreover, some endocytic proteins are ubiquitinated themselves, thus suggesting that 
some UBDs may mediate interactions not only with the cargo but also with proteins 
involved in the endocytic network (129).  
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4.2 Ubiquitination of endocytic adaptors  
As previously mentioned, several components of the downstream endocytic machinery, 
such as Eps15, Eps15L1, epsin1, epsin2, Hrs, Stam and Rabex5, are also modified by 
monoubiquitination upon RTK activation (22,127,130-132). For many of them, this 
process takes place following the stimulation of cells with growth factor (22,133). Many of 
these endocytic proteins, including Cin85, epsins, and eps15 family proteins, are known to 
undergo coupled monoubiquitination (127), which strictly depends on the ability of the 
UIM to bind to monoubiquitin.  
The precise role of adaptor monoubiquitination in RTK endocytosis is still a matter 
of debate. Monoubiquitination of adaptors might be responsible for sorting the receptor 
along the endocytic pathway by allowing binding of ubiquitinated cargoes (through 
UBDs), thus resulting in signal amplification and progression of ubiquitinated cargoes 
along the route (134). Alternatively, it has been recently proposed that this modification 
could represent a signal to “switch off” the binding activity of the adaptor (or of other 
endocytic proteins that undergo the same process), by allowing intramolecular interactions 
between the UBD and the Ub moiety present in cis (132). This mechanism might in turn 
harbour a series of consequences, for instance, the release of ubiquitinated cargo that 
would thus become available for the next level of interactions along the endocytic route. A 
validation of this possibility was shown through an Eps15-Ub chimera, created by the 
fusion of ubiquitin to the C-terminus of Eps15 to mimic its permanent ubiquitination. This 
construct fails to localize properly on endocytic vesicles containing internalized EGFR, 
thereby preventing the interaction between the UIMs contained in Eps15 and EGFR-Ub, 
and efficient endocytosis and degradation of the receptor (132). Furthermore, an HRS-
ubiquitin chimera loses its ability to recognize and sort ubiquitinated cargo (132). 
However, this evidence is based exclusively on artificial constructs. More studies are 
required to clarify the role of monoUb in the endocytic process. 
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4.3 Ubiquitin in endosomal sorting 
Ubiquitin plays a critical role at later steps of the endocytic cascade, in the endosomal 
sorting process. Ligand-induced ubiquitination is indeed required for lysosomal targeting 
and downregulation of signalling receptors (135). Importantly, there is a continuous 
process of ubiquitination and deubiquitination of EGFRs all along the endocytic pathway, 
which is crucial to fine tune and regulate EGFR ubiquitination levels. For instance, in the 
case of the EGF receptor, the E3 ligase c-Cbl (Casitas B-lineage lymphoma) remains 
associated with the receptor and promotes receptor ubiquitination all along the endocytic 
route, therefore ensuring that receptors are sorted to multivesicular endosomes and targeted 
for lysosomal degradation (127,136-139). There are also different DUBs acting along the 
pathway at the level of endosomes, multivesicular bodies and lysosomes [e.g. AMSH, 
UBPY (140)] that may counterbalance the action of c-Cbl. EGFR degradation is regulated 
by two best studied deubiquitinating enzymes that reside in the MVB, named STAM-
binding protein (STAMBP; also known as AMSH) and ubiquitin isopeptidase Y (UBPY, 
also knowkn as USP8) (141). Both the enzymes interact with ESCRT-0, the complex 
involved in the initial sorting of receptor for degradation (142). In line with this, 
conditional inactivation of the gene encoding for UBPY reduces the expression of several 
RTKs (143). 
The ESCRT complexes machinery orchestrates the ubiquitin-directed sorting into 
MVBs (144) (discussed in section 2.1). This conserved machinery performs three distinct 
but related functions: first, it recognizes ubiquitinated cargoes and prevents their recycling 
and retrograde trafficking; second, it bends the endosomal membrane, allowing cargo 
sorting into endosomal invaginations; third, it catalyzes the final abscission of the 
invaginations, forming the ILVs that contain the sorted cargo (145). Genetic KD of various 
subunits of ESCRT -0, -I, -II or –III strongly inhibits EGF-mediated lysosomal degradation 
of EGFRs (144,146). In addition, an isoform of Eps15 that associates to Hrs, Eps15b, is 
required for efficient lysosomal degradation of endocytosed EGFRs (147). What is the 
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exact mechanism of action of this protein in EGFR trafficking is still unknown, but the fact 
that it contains two C-terminal ubiquitin-interacting motifs suggests that it may contribute 
to increase the avidity of ESCRT-0 for ubiquitinated receptors. 
Since the rate of receptor downregulation and MVB targeting typically correlates 
with the extent of receptor ubiquitination in endosomes, interference with this 
posttranslational processing enhances signalling, as observed for mutants in EGFR 
ubiquitination sites (148). Similarly, RNA or genetic interference with the Ub adaptor Hrs 
in mammalian cells results in enhanced signalling by various RTKs, including EGFR, Met 
and VEGFR (vascular endothelial growth factor receptor) (149). Furthermore, genetic 
disruption of members of the ESCRT complexes, which are required for membrane fission 
events, including those that lead to endosomal ILV formation, results in sustained EGFR 
signalling (144). Thus, ubiquitination levels need to be tightly controlled to avoid excess of 
signalling. 
 
Figure 10 Ubiquitination in receptor endocytosis and endosomal sorting. Following 
ligand binding, EGFR can undergo clathrin-mediated endocytosis (right) or clathrin-
independent endocytosis (left). In both cases, receptors are routed to early endosomes, 
from where they can be sorted into ILVs of the MVE and subsequently targeted for 
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lysosomal degradation (ubiquitinated receptors) or recycled to the plasma membrane (non-
ubiquitinated receptors). Ubiquitin is an essential signal for endosomal sorting of EGFRs 
into the ILVs of MVEs. Components of the endocytic machinery, including Eps15, epsins, 
the ESCRT-0 components HRS and STAM, the ESCRT-I components TSG101 and 
Mvb12p (in yeast) (and the novel ESCRT-I component UBAP1), the ESCRT-II 
component VPS36 (EAP45), as well as EPS15b and GGA3 contain ubiquitin-binding 
domains have been implicated in recognizing and sorting ubiquitinated receptors either at 
the plasma membrane or at endosomes. The ESCRT-I and -II components assemble in 
supercomplexes and have been proposed to organize buds at the endosomal membrane. 
The ESCRT-III complex associates with ESCRT-II and forms polymers that drive 
membrane scission and ILV biogenesis. DUBs catalyze the removal of ubiquitin from 
receptors before their translocation into the ILV, without allowing cargo to escape (150). 
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5 Cbl proteins 
The extracellular stimulation of transmembrane receptors leads to the activation of 
signalling networks that transmit the information throughout the cell. This is achieved 
through the assembly of protein complexes that convey or inhibit a signal. An important 
regulation of the signal transduction involves Cbl proteins, a well-conserved family that 
controls multiple cellular processes, by acting both as ubiquitin ligases and as multiadaptor 
molecules (3). 
The first member of the Cbl family to be discovered was v-Cbl, a retroviral gene 
encoding a protein of 357 aminoacids, which was found to induce myelogenous leukemia 
and pre-B-cell lymphoma (151). Subsequently, it was discovered that v-Cbl corresponded 
to the truncated form of the larger cellular c-Cbl (152). c-Cbl encodes for a 120 kDa 
cytoplasmic protein that is ubiquitously expressed, in particular in thymus and testis (151).  
The mammalian Cbl proteins family comprises other two members, Cbl-b and Cbl-
3 (or Cbl-c); the former is mostly found in mature T cells while the latter is expressed at 
low levels in hematopoietic tissue (153,154). Orthologues in Drosophila melanogaster (D-
CblL; D-CblS) and Caenorhabditis elegans (SLI-1) have also been identified (155,156) 
(Figure 11). 
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Figure 11 Members of the Cbl proteins family.  Domain structure and length of 
mammalian Cbl, Cbl-b and Cbl-c, Drosophila melanogaster D-Cbl short and long, 
Caenorhabditis elegans SLI-1 are depicted. The amino-terminal PTB domain is composed 
of a four-helix boundle (4H), a calcium-binding EF hand and a divergent SH2 domain. The 
PTB domain, together with the linker region (L) and RING finger (RF), is the most 
conserved region in all the proteins. The long Cbl homologues have an extended carboxy-
terminal part with proline-rich sequences (Pro-rich), several tyrosine and serine 
phosphorylation sites and a leucine zipper/ubiquitin-associated domain (LZ/UBA). The top 
scale indicates amino acids positions based on the human c-Cbl (Cbl) sequences (157). 
 
5.1 Cbl proteins structure 
All the above-cited Cbl proteins show a high degree of sequence similarity in the N-
terminus, which encompasses a phosphotyrosine binding domain, a short helical linker 
region and a RING finger domain. The phosphotyrosine binding domain, also called TKB 
(tyrosine kinase binding) domain, contains a four-helix bundle (4H), a calcium-binding EF 
hand and a modified Src homology 2 domain (SH2) (158). This domain is connected to the 
RING finger through a linker region, which directs the correct positioning of the TKB 
domain towards the RING thus allowing the spatial orientation for the substrate and the E2 
loading enzyme (159). Another highly conserved region is the zinc-binding C3HC4 RING 
finger domain, which recruits E2 ubiquitin conjugating enzymes and mediates the transfer 
of molecules of ubiquitin on the target (160,161). 
Among the different members, the most divergent part of the protein is the C-
terminal sequence. Indeed, while c-Cbl, Cbl-b and D-CblL (Drosophila-Cbl Long isoform) 
have extensive proline-rich regions that contain various putative SH3-binding motifs 
(151,152), Cbl-c and SLI-1 have a very short proline rich region (153,156), which is absent 
in the short form of D-Cbl. Moreover, the carboxyl-terminal part extends with an acidic 
box domain with serine/threonine- and tyrosines that can be phosphorylated upon stimulus 
and ends with a leucine zipper domain that mediates dimerization (162) and a UBA motif 
that binds to ubiquitin residues (163). Yet, it has been demonstrated that both c-Cbl and 
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Cbl-b show homo- and hetero-dimerization ability and this property was found to be 
necessary for efficient c-Cbl tyrosine phosphorylation upon EGF and therefore, its 
association with the EGFR (164). However, only Cbl-b and not c-Cbl can bind ubiquitin 
moieties (165). 
These multiple binding motifs allow Cbl proteins to interact with a plethora of 
proteins through distinct mechanisms (Figure 12). For example, c-Cbl interacts with the 
EGFR directly through its TKB domain and indirectly via an SH3 domain-mediated 
interaction with Grb2 (Growth factor receptor-bound protein 2) (166). The RING finger 
domain recruits E2 ubiquitin-conjugating enzymes (159) and also binds its negative 
regulator Sprouty2 (167). The proline rich region mediates interactions with SH3-
containing proteins, such as Sts1-2, Src family PTKs (phospho-tyrosine kinases) and p85 
(168-170). Within this proline-rich region a small serine-rich domain provides docking site 
for 14-3-3 proteins binding (171). At the C-terminus, c-Cbl contains 22 tyrosine residues 
and those at 700, 731 and 774 are the major phosphorylation sites (172) by Syk and Src-
family kinases Fyn, Yes and Lyn (172). Phosphorylation at Y700 and Y774 represents 
docking site for the SH2 domain of the adaptor protein Crk (173). 
This intricate picture suggests that c-Cbl activity needs to be tightly regulated and 
that c-Cbl can have multiple roles in endocytosis, both as E3 ligase and adaptor; one of the 
aims of this project was indeed to dissect the two functions. 
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Figure 12 c-Cbl interacts with many signalling proteins. After cell surface stimulation 
c-Cbl is recruited to the activated receptor and in turn, recruits several other signalling 
proteins. The TKB domain binds phosphorylated tyrosines on the substrate; the RING 
finger domain recruits Ub-conjugating enzymes that allow its E3 ligase activity. c-Cbl also 
becomes phosphorylated on tyrosine (Y) and serine (S) residues, by promoting 
associations with SH2-domain-containing proteins and 14-3-3 proteins, respectively. Some 
associations are constitutive, such as those with the numerous SH3-domain-containing 
proteins that bind one or more of the 15 SH3-binding motifs within the extensive proline-
rich regions. (CAP, Cbl-associated protein; CIN c-Cbl- interacting protein; CMS, Cas 
ligand with multiple SH3 domains; EGFR; PDGFR, platelet-derived growth factor 
receptor; PI(3)K; SETA, SH3-encoding, expressed in tumorigenic astrocytes; UBA; ZAP-
70, z-chain-associated protein kinase 70) (174). 
 
5.2 Cbl proteins as regulators of RTKs 
Cbl proteins have been identified as negative regulators of RTKs when genetic 
experiments in C. elegans demonstrated that Sli-1 is a suppressor of EGFR/LET-23 
signalling in this organism (156). In agreement with these studies, Levkowitz and 
colleagues showed that c-Cbl was able to ubiquitinate and downregulate the EGFR 
(137,161), an ability that requires an intact TKB and RING finger domain (161) (for the 
role of c-Cbl in EGFR ubiquitination see section 7.1).  
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Since then, c-Cbl has been shown to ubiquitinate other RTKs, e.g. EGFR 
(148,175), VEGFR (176), PDGFR (160), FGFR (Fibroblast Growth Factor Receptor) 
(177) and HGFR (hepatocyte growth factor receptor) (178) (Table 2). 
 In the case of HGFR (also known as c-Met receptor), the molecular mechanism of 
its ubiquitination has been widely investigated. Stimulation of HGFR with its ligand, the 
hepatocyte growth factor (HGF), leads to receptor ubiquitination by c-Cbl and increased 
degradation (178). This requires a functional c-Cbl TKB domain and the Y1033 located in 
the juxtamembrane region of the receptor. Indeed, the E3 ligase c-Cbl is recruited to the 
HGFR directly through its TKB domain that binds the pY1033 and indirectly, via its 
proline-rich domain, through the adaptor protein Grb2, which binds to the pY1356 on the 
receptor (178). The substitution of Y1033 with phenylalanine abrogates the recruitment of 
c-Cbl to the HGFR and its consequent ubiquitination (178). Moreover, an intact indirect 
binding site for c-Cbl recruitment is not able alone to efficiently induce HGFR 
ubiquitination (178). Noteworthy, this modality of c-Cbl recruitment could be envisioned 
for other RTKs [e.g. Ret and EGFR (see section 7)].  
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Table 2 Tyrosine kinases receptors regulated through ubiquitination. The RTKs 
together with the E3 ligase described for their ubiquitination and the type of ubiquitination 
are shown in the table (135). 
 
5.3 Regulation of c-Cbl functions 
Cbl proteins are highly regulated within the cells, both by degradation but also by specific 
inhibitors, which act through different mechanisms. Several studies have shown that 
degradation of Cbl proteins is a regulated process that can potentially control RTKs 
activity. Different mechanisms, comprising both auto-ubiquitination and ubiquitination by 
other E3 ligases, seem to be involved in the degradation of Cbl proteins (179).  
Activated forms of Src kinase induce ubiquitination and proteasomal degradation 
of c-Cbl (180) thus preventing downregulation of the activated EGFR by c-Cbl (180) 
(Figure 13). Moreover, c-Cbl colocalizes with activated Src in structures similar to those 
observed for the activated EGFR, suggesting that Src induces c-Cbl degradation 
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throughout the endocytic pathway (180). In addition, activated Src enhances the 
transforming activity of the EGFR, and this might be in part explained by degradation of 
the Cbl proteins (180). 
 Another regulatory mechanism involves the HECT E3 ligases Nedd4 and Itch, 
which bind to and ubiquitinate all the mammalian Cbl proteins, targeting them to 
proteasomal degradation (181) (Figure 13). Consistent with these observations, Nedd4 
prevents c-Cbl-mediated ubiquitination and downregulation of the EGFR, thereby resulting 
in the persistence of downstream signalling by the EGFR (181). 
 Recently, two c-Cbl interacting proteins (Sts-1 and Sts-2) have been found to 
regulate the action of c-Cbl on RTKs signalling (170). Upon EGFR activation, Sts-1 and 
Sts-2 are recruited to the EGFR and inhibit its ubiquitination by the E3 ligase c-Cbl that 
leads to receptor downregulation. Sts-1 and Sts-2 can compete with epsin proteins and 
associate to activated and ubiquitinated EGFR through their UBA domain (170). The 
mechanism of inhibition is still poorly understood; however, competition with the sorting 
machinery during receptor endocytosis could be important. 
 A well-studied example of regulation of c-Cbl functions is achieved through 
Sprouty2; Cbl proteins bind constitutively but weakly to Sprouty via the RING finger 
domain (182). Upon growth factor stimulation, Sprouty2 expression is induced and the 
protein is moved to the plasma membrane where it becomes phosphorylated on Tyr55. c-
Cbl binds to this phosphorylated residue through its TKB domain with high affinity 
(182,183). This interaction results in ubiquitination and proteasomal degradation of 
Sprouty2 (182,183). Phosphorylated Sprouty2 also competes with the activated EGFR for 
the binding to the TKB domain of c-Cbl, and this leads to a decrease in Cbl-mediated 
ubiquitination and downregulation of the receptor (182,183) (Figure 13). 
Cdc42 is another example of a protein that competitively inhibits the 
downregulation of the EGFR by Cbl proteins. Upon EGF stimulation, Cdc42 is activated 
and binds to the β-Pix protein, which in turn interacts with the proline rich region of c-Cbl 
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(184). This complex sequesters c-Cbl and prevents its binding to the EGFR, thereby 
inhibiting ubiquitination and downregulation of the activated EGFR (184) (Figure 13).    
  
 
Figure 13 Different mechanisms of c-Cbl regulation. On the left panel regulation with 
degradation is shown. Cbl proteins are degraded by various mechanisms, including their coordinate 
degradation along with the EGFR, degradation by Src and degradation by Nedd4. c-Cbl is also 
degraded along with the EGFR in the lysosome. On the right panel, regulation without c-Cbl 
degradation is depicted. The two major proteins involved in this mechanism are the inhibitor 
Sprouty (Spry) proteins the GTPase Cdc42 (179). 
 
All the above-described mechanisms concern negative regulation of c-Cbl activity. 
But c-Cbl activity is also positively regulated. A crucial mechanism of activation is 
achieved through c-Cbl phosphorylation by EGFR. Indeed, EGFR can phosphorylate the 
Tyr371 located in the linker region of c-Cbl. The E3 ligase activity of c-Cbl is stimulated 
by Tyr371 phosphorylation, and although previous in vitro and in vivo studies clearly 
support phosphoregulation of the ligase activity of c-Cbl through this tyrosine (161,185), 
the detailed mechanisms underlying this positive regulation of c-Cbl activity have not been 
described yet. However, recently, two structural studies have shed some light on the 
mechanism of c-Cbl and Cbl-b activation induced by phosphorylation (186,187). In the 
absence of substrate binding, the TKB and RING domains form a packed structure that 
masks the E2 binding site. The subsequent binding of the TKB to the substrate induces a 
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primary rotation of the linker region, which allows phosphorylation of Tyr371 in c-Cbl and 
Tyr363 in Cbl-b. This phosphorylation event leads to a complete rotation of the linker 
region that unmasks the RING E2 binding surface, allowing substrate ubiquitination 
(186,187). 
 
5.4 Functions of Cbl proteins in the immune system 
c-Cbl and Cbl-b proteins play crucial roles in controlling several functions of the immune 
system. Their essential role was demonstrated through the generation of mice deficient for 
c-Cbl (188) or Cbl-b (189,190). These two proteins display redundant functions, since c-
Cbl-/- and Cbl-b-/- double knockout (KO) mice are embryonic lethal (191), while single KO 
animals are viable and fertile (188-190). The major phenotypes observed in the single KO 
mice concern the alteration of signalling pathways in thymocytes or mature T cells. In 
detail, c-Cbl-deficient mice show increased TCR (T cell receptor) signalling in thymocytes 
involving the upregulation of the activity of the kinase ZAP70 (188). On the contrary, Cbl-
b deficient mice display alterations of TCR in mature pheripheral T cells through 
deregulation of Vav guanine nucleotide exchange factor activity (189,190). c-Cbl-/- mice 
exhibit increased thymic cellularity and splenomegaly (188), consistent with the ability of 
c-Cbl to negatively regulate mitogenic signals. On the contrary, no aberrant thymic 
development has been demonstrated in Cbl-b-/- mice, although they display spontaneous 
(189) or induced autoimmunity disorders (190). The distinct phenotypes observed between 
c-Cbl-/- and Cbl-b-/- mice, may reflect differences in the expression of the two proteins 
between thymocytes and peripheral T cells. Thus, c-Cbl KO mice have raised interesting 
questions about the abilities of c-Cbl and Cbl-b to negatively regulate different signalling 
molecules in distinct T-cell populations. Some studies suggest that Cbl-b might act 
preferentially in the regulation of exchange factors for Rho-family GTPases rather than 
tyrosine kinases (192).  
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5.5 c-Cbl mutations from myeloid neoplasm to Noonan syndrome and solid tumors 
Over the past 5 years, c-Cbl has been found mutated in almost 5% of a wide variety of 
myeloid neoplasms, including myelodysplastic syndrome, myelofibrosis, de novo and 
secondary acute myeloid leukemia (respectively AML and sAML), atypical chronic 
myelogenous leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and chronic 
myelomonocytic leukemia (CMML) (193-199) (Cosmic. Catalogue of Somatic Mutations 
in Cancer. 2012. Available from : http://www.sanger.ac.uk/genetics/CGP/cosmic/). The 
frequency of c-Cbl mutations is spread throughout these diseases; it appears to be higher in 
JMML (15%), CMML (13%), sAML (10%), and aCML (8%). The majority of these 
mutations are missense mutations that cluster within the linker region and the RING finger 
domain (Figure 14) and have been shown to disrupt the E3 ligase activity. These missense 
mutations are usually homozygous mutations, resulting from copy neutral loss of 
heterozygosis; on the contrary, the deletions that arise from splicing mutations are more 
frequently heterozygous (193-199). Nonsense mutations, frame shift mutations and 
insertions within the linker and RING finger regions have been found as well. Functional 
studies have demonstrated that the c-Cbl mutants found in myeloid neoplasm loose E3 
ligase activity, thus causing increased activity of the receptor tyrosine kinase Flt3, and 
downstream signalling of PI3K and STAT pathways; indeed they are transforming 
(193,196,199). One possibility of action of these mutants is that they act as dominant 
negative proteins on the endogenous c-Cbl (when is in heterozygosis) or on Cbl-b, by 
uncoupling c-Cbl binding to activated RTKs from their ubiquitination and degradation. In 
support of this, while deficient mice in c-Cbl, Cbl-b or Cbl-c do not show any evidence of 
leukemia, mice carrying a RING finger mutant c-Cbl knock-in develop leukemia (200), by 
suggesting that wild type c-Cbl may act as tumor suppressor, while mutant c-Cbl might 
function as oncogene. 
Mutations in Cbl-b and Cbl-c are much less common in myeloid neoplasm. Only 
two studies have described frame shift or missense mutations within the RING finger 
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domain of Cbl-b (194,198). The fact that no other studies have found Cbl-b mutations 
suggests that the frequency of Cbl-b mutations in myeloid neoplasm is lower compared to 
c-Cbl (193,196). Moreover, only one report describes polymorphism in the RING finger 
domain of Cbl-c (198); however, the expression of Cbl-c is restricted to epithelial cells, so 
the importance and significance of these abnormalities remain to be elucidated (154). 
Heterozygous germline mutations in c-Cbl can underlie a phenotype with clinical 
features fitting or partially overlapping Noonan Syndrome (NS) (201). The Noonan 
Syndrome is transmitted as an autosomal dominant trait and is genetically heterogenous 
(202). It is a clinically variable condition characterized by reduced postnatal growth, a 
wide spectrum of cardiac diseases, facial dysmorphism and ectodermal and skeletal defects 
(203). c-Cbl mutations associated with this disease are missense mutations that alter 
evolutionary conserved residues located in the RING finger domain and in the linker 
region (Figure 14), two known mutational hot spots in myeloid malignancies above 
described (201). The mutations found in c-Cbl have been shown to affect c-Cbl-mediated 
receptor ubiquitination and to cause an aberrant signal flux through RAS and the MAPK 
signalling cascade (201,202). 
 Somatic mutations of c-Cbl have been found in 8 NSCLC out of 119 samples 
(204). All but one of the mutations are located outside the RING finger (Figure 14) and are 
all heterozygous. These mutants have been characterized for their effect on E3 ligase 
activity, cell viability, cell cycle and cell motility: the E3 ligase activity is maintained, 
while their overexpression causes increased viability and motility (204). However, the 
relevance and significance of these mutations still needs to be established.  
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Figure 14 Mutations of c-Cbl in cancer and Mendelian diseases. In the middle of the 
panel, a schematic of the c-Cbl protein is depicted with its functional domains (LR, linker 
rregion; RF, RING finger domain). The ruler underneath shows amino acid positions. On 
the top, the position and the frequency of the mutations detected in myeloproliferative 
diseases are shown by solid circles, aligned with the amino acid sequence. At the bottom, 
the position of the mutations detected in NSCLC and in the Noonan-like syndrome is 
shown by red and green arrows, respectively. In NSCLC, the mutation at position 391 was 
detected in two tumors (shown as x2). In the Mendelian syndrome, four of five mutations 
affect the same residues (371, 367, 382, 420) as in myeloproliferative diseases (4). 
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6 The EGFR system 
Receptor tyrosine kinases have been widely described as key regulators of critical cellular 
processes, such as proliferation, differentiation, cell survival and metabolism, cell 
migration and cell-cycle control (205). The EGFR is a prototypical RTK (206) with critical 
roles in physiological and pathological processes in epithelial cells (207). The EGFR, also 
named ErbB1, belongs to a family that includes three other members: ErbB2/HER-2 (208), 
ErbB3/HER-3 (208), and ErbB4/HER-4 (209). These receptors share a similar structure 
that is composed by an extracellular ligand-binding domain, which has four subdomains (I-
IV), a short hydrophobic transmembrane helix, and a cytoplasmic region that contains the 
protein tyrosine kinase domain and an additional carboxy-terminal and juxtamembrane 
regulatory regions (210). This structure enables signals to be transmitted across the plasma 
membrane where they activate gene expression and ultimately induce different cellular 
responses.  
A number of distinct ligands activate the receptor by binding to the extracellular 
domain, such as EGF, transforming growth factor-α (TGFα), heparin-binding EGF-like 
growth factor (HB-EGF), amphiregulin (AR), betacellulin (BTC), epiregulin (EPR) and 
epigen (211-215). All ErbB family ligands are made as type I transmembrane proteins that 
are inserted into the plasma membrane and then cleaved by cell surface proteases to release 
mature growth factor that binds the receptor.  
Like other transmembrane proteins, EGFR is co-translationally translocated 
through the endoplasmic reticulum (ER) membrane, transported to the Golgi apparatus, 
where the extracellular domain becomes N-linked glycosylated. From here, EGFR is 
delivered to the plasma membrane (216). 
Increasing evidence indicates that, in unstimulated cells, EGFR might exist both in 
a monomeric and in a pre-dimerized state (217). It is now well accepted that binding of 
EGF (or other agonists) to EGFR shifts a monomer-dimer equilibrium to favour the 
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dimeric state (218,219). Ligand binding to the pre-dimerized state forms a 2:2 ligand to 
receptor configuration and induces a rearrangement of each receptor subunit, allowing a 
rotation of the transmembrane domain (220). The transition to ligand-bound receptor 
dimers releases inhibitory interactions that maintain the inactive form of the receptor. 
These conformational changes induce activation of the intracellular tyrosine kinase domain 
and consequent trans-autophosphorylation of key tyrosine residues within the COOH-
terminal portion of EGFR and, as a result, provide specific docking sites for cytoplasmic 
proteins containing SH2 and phosphotyrosine binding domains. These multiple bindings 
initiate intracellular signalling via several pathways (210), thereby inducing multiple 
responses in the cell (Figure 15). 
EGFR phosphorylation is counterbalanced by the action of protein Tyr-specific 
phosphatases (PTPs), which reverse Tyr phosphorylation on EGFR residues. The PTP 
superfamily includes both cytoplasmic enzymes and transmembrane receptor-like PTPs 
(RPTPs). Although protein-Tyr phosphatase 1B (PTP1B) resides in the endoplasmic 
reticulum, it has been implicated in EGFR signalling (221). Additional RTK-PTP 
interactions take place at the plasma membrane and in endosomes. However the exact 
impact of phosphateases on EGFR at the plasma membrane is still a matter of 
investigation. 
As we discussed previously, c-Cbl is recruited to specific tyrosines in the EGFR 
tail upon receptor activation at the plasma membrane and catalyzes ubiquitination of the 
EGFR (see also next section). Importantly, c-Cbl-mediated ubiquitination starts already at 
the plasma membrane and continues in the endocytic compartments (222). Indeed, c-Cbl 
remains associated all along the endocytic route (136,222) counteracting the action of 
deubiquitinating enzymes at the endosomal stations (141). c-Cbl-mediated ubiquitination is 
required to target EGFRs to lysosomal degradation, leading to signal extinction (137-
139,175). Whether ubiquitination is essential also at the initial steps of EGFR 
internalization is rather controversial and will be discussed more in details in section 7.1. 
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Figure 15 The ErbB signalling network. a Ligands and the ten dimeric receptor 
combinations comprise the input layer. Numbers in each ligand block indicate the 
respective high-affinity ErbB receptors. For simplicity, specificities of receptor binding are 
shown only for EGF and neuregulin 4 (NRG4). ErbB2 binds no ligand with high affinity, 
and ErbB3 homodimers are catalytically inactive (crossed kinase domains). Trans-
regulation by G-protein-coupled receptors [such as those for lysophosphatidic acid (LPA), 
thrombin and endothelin (ET)], and cytokine receptors is shown by wide arrows. b 
Signalling to the adaptor/enzyme layer is shown only for the weakly mitogenic ErbB1 
homodimer, and the relatively potent ErbB2–ErbB3 heterodimer. Only some of the 
pathways and transcription factors are represented in this layer. c Translation of the 
pathways into specific types of output (210).  
 
6.1 Ligand-induced EGFR signal transduction 
The ErbB network has been described as a bow-tie structure, where the inputs of multiple 
growth factors function through eight potential hetero-homodimers receptors and activate 
common signalling cascades (223). This process results in the specific activation of 
transcription factors that lead to the selected cell fate. Temporal and spatial control of 
EGFR signalling dictates its biological outcome possibly by altering the balance among 
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various signalling pathways (224). As above mentioned, EGFR can be activated by several 
ligands, each of which is characterized by a consensus sequence consisting of six spatially 
conserved cysteines residues that create three intermolecular disulfide bonds. This 
consensus sequence is known as the EGF motif (225). 
Upon ligand binding, EGFR triggers several downstream signalling pathways similar to 
other RTKs. These pathways include: 
(1) the activation of PLCγ and its downstream calcium- and PKC-mediated cascades;  
(2) the activation of Ras signalling, leading to various MAPKs; 
(3) the activation of PI3K, leading to AKT signalling cascade; 
(4) the activation of signal transducers and activators of transcription (STAT) pathway; 
(5) the activation of Src kinase. 
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7 EGFR endocytosis  
Activation of EGFR through binding of EGF leads to acceleration of receptor endocytosis. 
EGFR can be internalized through both CME and NCE pathway (1) and the distribution of 
the receptor into these two entry routes is a highly regulated process, which has a major 
impact on the final fate of the EGFR (92). CME is characterized by high internalization 
rates of EGFR and is observed already when EGF is used at low concentrations (≤1-2 
ng/ml), whereas the apparent rate of EGF uptake decreases with increasing EGF 
concentrations, as clathrin-independent pathways become active, in different cellular 
contexts (226). There has been a long controversy in the field regarding the establishment 
of accepted physiological concentrations of EGF, since there was a historical erroneous 
perception that only low doses of EGF could be physiological. However, it is known that 
while plasma EGF concentrations are around 1 ng/ml (227), serum EGF levels are 
significantly higher (228,229), possibly because of the release of EGF from platelets by 
degranulation (228) (Table 3). Moreover, different organs seem to regulate their levels of 
EGF in an independent fashion, further confirming the notion that EGF might act locally 
rather than systemically as an endocrine factor. Indeed, great differences of EGF 
concentrations have been observed in various fluids of the body, from low concentration 
(1–5 ng/ml) in plasma, serum, and saliva (227-229), to medium amount (5–50 ng/ml) in 
tears, follicular fluid, sperm, and seminal plasma (227,229,230), to high levels (50–500 
ng/ml) in bile, urine, milk, and prostate fluid (227,231,232) (Table 3). Therefore, under 
physiological conditions, EGFR-expressing cells are exposed to a wide range of EGF 
ligand concentrations, ranging from a few to a few hundred ng/ml. 
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Table 3 Concentration of EGF in human tissues and bodily fluids. The concentration 
of EGF is locally regulated and varies in different tissues and bodily fluids.  
 
Recent studies from our laboratory have shown that ligand concentration can affect 
the internalization route (1). In particular, at low doses of EGF (<3 ng/ml), receptors 
undergo exclusively CME (1). On the contrary, higher ligand concentration (10-100 ng/ml) 
induces a substantial proportion of receptors (~40%) to undergo NCE (1). Moreover, 
EGFRs internalized through CME are mostly not targeted to lysosomal degradation but 
rather recycled back to the plasma membrane. This results in a prolonged duration of 
activated-EGFR signalling pathways (92). By contrast, EGFRs entering cells through 
clathrin-independent endocytosis are preferentially targeted to degradation, thus leading to 
signal extinction (92). Interestingly, this dual mechanism seems to cope with the huge 
variety of physiological EGF concentration present in body fluids. When cells need to 
maximize the stimulation efficiency (i.e. at low doses of ligand), this mechanism sustains 
signalling and protects receptors from degradation; when the ligand is present at high 
concentration, it protects cells from overstimulation by targeting excess of activated 
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EGFRs to degradation (92). However, not all cells have this dual mechanism, and the 
presence and significance of EGFR-NCE clearly depends on the cellular context at least in 
culture (226,233) (Table 4). 
  
Cell Line 
EGFRs/cell  
LOW EGF 
Ke 
HIGH EGF 
Ke obs NCE 
HeLa Milan 
3.0 x 105 
Control 0.30 0.15 
YES 
Cl-KD 0.08 0.08 
Fil. 0.30 0.08 
Cl-KD+Fil. 0.08 0.03 
Dyn-KD 0.07 0.03 
HeLa Milan EGFR 
KD 
0.7 x 105 
Control 0.24 0.32 
YES Cl-KD 0.09 0.23 
Fil. 0.21 0.24 
Cl-KD+Fil. 0.07 0.04 
HeLa Oslo 
0.8 x 105 
Control 0.30 0.30 
NO Cl-KD 0.08 0.08 
Fil. 0.03 0.30 
Cl-KD+Fil. 0.08 0.08 
NR6-EGFR wt 
2.5 x 105 
Control 0.11 0.11 
YES Cl-KD 0.03 0.06 
Fil. 0.11 0.08 
Cl-KD+Fil. 0.03 0.03 
A431 
1.4 x 106 
Control 0.42 0.05 
YES Cl-KD 0.07 0.03 
Dyn-KD 0.08 0.01 
MDA MB-231 
0.8 x 105 
Control 0.24 0.19 
YES Cl-KD 0.04 0.08 
Dyn-KD 0.03 0.02 
BT20 
4.3 x 105 
Control 0.10 0.06 
YES Cl-KD 0.03 0.04 
Dyn-KD 0.03 0.02 
MCF10A 
2.9 x 105 
Control 0.27 0.19 
NO Cl-KD 0.04 0.02 
Dyn-KD 0.02 0.04 
HCT116 
0.5 x 105 
Control 0.23 0.24 
NO Cl-KD 0.04 0.05 
Dyn-KD 0.04 0.05 
BT549 
0.5 x 105 
Control 0.23 0.13 
NO Cl-KD 0.04 0.02 
Dyn-KD 0.04 0.02 
 
 
Table 4 Presence of EGFR-NCE in various cell lines. The presence of an EGFR-NCE 
pathway in the indicated cell lines has been evaluated by comparing the internalization 
curves of WT versus clathrin-KD cells or dynamin-KD, or by comparing WT versus 
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filipin-treated cells, and calculating the endocytic rate constants (Ke or Ke obs, see section 
1 , Results) (226). 
 
So how does EGF dosage influence the selection of a particular endocytic 
pathway? Recent work performed in our lab (226) has shown that the same range of EGF 
concentration that activates EGFR NCE also causes a sharp increase (“threshold”) in 
EGFR ubiquitination. It is this covalent modification of the EGFR that functions as a 
“switch” that commits receptors to NCE. The molecular mechanism governing the switch 
depends on the cooperative recruitment of c-Cbl to the EGFR: as a consequence of EGF 
binding, the EGFR becomes multiply phosphorylated, a modification that permits the 
cooperative binding of the E3 ligase c-Cbl, in complex with Grb2, at two specific EGFR 
phosphorylation sites. A higher concentration of EGF results in a greater probability of 
EGFR being sufficiently phosphorylated at both critical sites to allow c-Cbl/Grb2 binding. 
Efficient recruitment of c-Cbl induces massive EGFR ubiquitination and triggers its 
internalization via NCE (150). Thus, c-Cbl binding to the EGFR allows cells to react to a 
linear gradient of ligand with a threshold ubiquitination response that, in turn, regulates 
EGFR internalization via NCE, and ultimately EGFR fate and signalling capacity. 
 
7.1 Role of c-Cbl in EGFR endocytosis 
c-Cbl is the major E3 ligase involved in EGFR ubiquitination along the endocytic pathway 
(136); in addition, through its ligase activity, c-Cbl can ubiquitinate, not only the receptor, 
but also other proteins involved in the internalization process (3). In addition, as we 
discussed above, the multi-domain nature of c-Cbl allows the protein to interact with 
numerous partners. Therefore, beside its role as E3 ligase, c-Cbl can bind and/or regulate 
around 150 different proteins [reviewed in (3)], making it difficult to separate its E3 ligase 
activity and adaptor function in EGFR endocytosis. One of the aims of my PhD was indeed 
to dissect this dual role in EGFR clathrin-mediated endocytosis. 
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Several experimental data support the role of c-Cbl in EGFR internalization via CME. 
Firstly, it has been demonstrated EGF-induced translocation of c-Cbl to CCPs (136). 
Secondly, overexpression of several c-Cbl mutants inhibits EGFR internalization in 
different cell lines, including HeLa, PAE and NIH3T3 cells (234,235). Thirdly, chimeric 
proteins composed by the SH2 domain of Grb2 and c-Cbl are able to rescue EGFR 
endocytosis in Grb2-depleted cells (236). Fourthly, siRNA depletion of both c-Cbl and 
Cbl-b through RNA interference partially inhibits EGFR clathrin endocytosis (148).  
Since c-Cbl ubiquitinates EGFR, it is logical to suppose that c-Cbl-mediated 
ubiquitination of EGFR is required for receptor internalization. However, the situation is 
complicated by the fact that distinct internalization pathways show a different requirement 
for receptor ubiquitination. Indeed, as previously discussed, EGFR ubiquitination is 
absolutely required for receptor internalization through NCE (1,226). However, its 
requirement for the initial steps of CME is rather controversial (150). In this sense, several 
lines of evidence exclude the requirement of c-Cbl-mediated EGFR ubiquitination in 
CME. The first indication came from an EGFR mutant that lacks Tyr1045 and is weakly 
ubiquitinated. This mutant undergoes normal internalization via CME (234). Recently, 
through a mass spectrometry analysis, the ubiquitination sites in EGFR have been mapped 
in the kinase domain of the receptor and it has been found that the two major modifications 
are the monoubiquitination (~49% of the modified receptor) and lys63-linked 
polyubiquitination (~40%) (148), although it is not clear whether they play a distinct role 
in endocytosis. Mutations of the major ubiquitination sites (16KR) do not affect EGFR 
CME, arguing that receptor ubiquitination is not essential for this pathway (2,148). 
Interestingly, the 16KR EGFR mutant still depends on c-Cbl for its internalization via 
CME. From these results, it emerges that although EGFR ubiquitination is not essential for 
CME, c-Cbl activity is still needed, possibly because of its adaptor function or because it 
ubiquitinates other endocytic components of the clathrin machinery. To better understand 
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the role of c-Cbl in EGFR endocytosis, further studies should focus on additional proteins 
that can mediate EGFR internalization through c-Cbl-Grb2 complex.  
 
 69 
 
Material ans methods 
1 Solutions 
1.1 Phosphate-buffered saline  
NaCl 137 mM 
KCl 2.7 mM 
Na2HPO4 10 mM 
KH2PO4 2 mM 
 
8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, and 0.24 g of KH2PO4 were dissolved in 
800 ml of distilled water. The pH was adjusted to 7.4 with HCl and the volume was 
brought to 1 litre with distilled H2O. 
 
1.2 Tris-HCl (1 M) 
121.1 g of Tris base were dissolved in 800 ml distilled H2O. The pH was adjusted to 7.4, 
7.6 or 8.0 with HCl, and distilled H2O was added to bring the volume up to 1 litre. 
 
1.3 Tris-buffered saline (TBS) 
NaCl 137 mM 
KCl 2.7 mM 
Tris HCl, pH 7.4 25 mM 
 
8 g of NaCl, 0.2 g of KCl and 3 g of Tris base were dissolved in 800 ml of distilled H2O. 
The pH was adjusted to 7.4 with HCl and distilled H2O was added to bring the volume up 
to 1 litre. 
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1.4 10X SDS-PAGE running buffer 
Glycine 192 mM 
Tris HCl, pH 8.3 250 mM 
SDS 1% 
 
1.5 10X Western transfer buffer 
Glycine 192 mM 
Tris HCl, pH 8.3 250 mM 
 
For 1X western transfer buffer, the 10X stock was diluted 1:10 with ddH2O and 20% v/v 
methanol or ethanol. 
 
1.6 50X TAE (Tris-Acetate-EDTA)  
Tris base 2 M 
Acetic acid 1 M 
EDTA, pH 8 10 mM 
 
The pH was adjusted to 8.5 with HCl and distilled H2O was added to bring the volume up 
to 1 litre. 
 
  
2 Protein buffers 
2.1 1X JS buffer 
HEPES, pH 7.4 50 mM 
NaCl 150 mM 
Glycerol 10% 
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Triton X-100 1% 
MgCl2 1.5 mM 
EGTA 5 mM 
 
2.2 1X RIPA buffer 
Tris HCl, pH 7.6 50 mM 
NaCl 150 mM 
NP-40 1% 
SDS 0.1% 
Deoxyxholic acid 0.5% 
EGTA 5 mM 
 
500X Protease inhibitor cocktail from Calbiochem, sodium pyrophosphate pH 7.5 20mM, 
sodium fluoride 250 mM, PMSF 2 mM, and sodium orthovanadate 10 mM were added to 
the buffer just before use. 
 
2.3 1X YY buffer 
HEPES, pH 7.4 50 mM 
NaCl 150 mM 
Glycerol 10% 
Triton X-100 1% 
EDTA 1 mM 
EGTA 1 mM 
 
500X Protease inhibitor cocktail from Calbiochem and PMSF 2 mM were added to the 
buffer just before use. 
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2.4 1X Laemmli buffer 
SDS 2% 
Tris HCl, pH6.8 62.5 mM 
Glycerol 10% 
Bromophenol blue 0.1% 
β.Mercaptoethanol 5% (v/v) 
 
SDS-PAGE sample buffer was prepared as a 5X stock solution and stored at -20°C, 
protected from light. 
 
 
3 Reagents  
Human recombinant EGF was from INALCO. 125I-EGF was from Perkin Elmer. 
Doxycycline hydrocloride was from SIGMA. 
 
3.1 Antibodies 
For western-blot, anti-EGFR [epitope: aa 1172-1186 (Homo sapiens)], anti-Eps15 
[epitope: aa 2-330 (Mus musculus)], anti-Eps15 human and anti-GST were produced in-
house through the Antibody Facility. Anti-pY(1068)EGFR, anti-pY(1045)EGFR were 
from Cell Signaling. Anti-CHC, anti-c-Cbl, anti-Grb2, and anti-Shc were from 
Transduction BD. Anti-HA was from BABCO. Anti-FK2 was from MIOBOL. Anti-pY 
was from Upstate. Anti-Cbl-b, anti-Eps15, anti-Tubulin, anti-Actin and anti-Ub (P4D1) 
were from Santa Cruz.  
 
 73 
3.2 RNAi oligos 
Negative control siRNA 
The negative control siRNA used in our assays was All Stars from Qiagen. 
Specific RNAi oligos 
Oligos used in experiments reported in the figures in the Results section: 
- c-Cbl human (Invitrogen): CCGAUUUGAGAUAGAGGCCUUUAAA 
- c-Cbl human (Invitrogen) : AUGAGAAGCUGCCUGGUCUAUUACU 
- Cbl-b human (Invitrogen): GAGAGAAGUGUCUCCUCCUCGUGUA 
- Cbl-b UTR2: UAAACAAGGUAAAGCAUUUCACAGG 
- c-Cbl mouse (Invitrogen): GAGUAUUUCAGGGUGUUCAUGGAAA 
- Cbl-b mouse (Invitrogen): GGAGCAGUAUGAACUGUAUUGUGAA 
- Grb2 (Dharmacon): CAUGUUUCCCCGCAAUUAU 
- Dynamin [Dharmacon (13)]: GACATGATCCTGCAGTTCA; 
GAGCGAATCGTCACCACTT 
- Clathrin Heavy Chain (Stealth Invitrogen): GAAGAACUCUUUGCCCGGAAAUUUA; 
 
3.3 TaqMAN assays for Q-PCR (Applied Biosystems) 
- C-CBL: hs00231981_m1 
- CBL-B: hs00969143_m1 
- CBL-C: hs00180288_m1 
- c-Cbl: mm01343092_m1 
- Cbl-b: mm00483069_m1 
- Eps15: mm00514740_m1 
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4 Cloning techniques 
4.1 Agarose gel electrophoresis 
DNA samples were loaded on 0.8%-1% agarose gels along with DNA markers (1 kb DNA 
Ladder, NEB). Gels were made in TAE buffer containing Gel Red (Biotium), according to 
manufacturer’s instructions, and run at 100 V until desired separation was achieved. DNA 
bands were visualized under a UV lamp. 
 
4.2 Minipreps 
Individual colonies were used to inoculate 3 ml LB (containing the appropriate antibiotic) 
and grown overnight at 37°C. Bacteria were transferred to Eppendorf tubes and centrifuged 
for 5 minutes at 16,000xg using a 5415 R centrifuge. Minipreps were performed with the 
Wizard Plus SV Minipreps Kit (Promega) following manufacturer’s instructions. The 
plasmids were eluted in 30 µl nuclease free H2O. 
 
4.3 Diagnostic DNA restriction 
Between 0.5 and 5 µg DNA were digested for 2 hours at 37°C with 10-20 units of 
restriction enzyme (New England Biolabs). For digestion, the volume was made up to 20-
50 µl with the appropriate buffer and distilled H2O. 
 
4.4 Large scale plasmid preparation 
Cells containing transfected DNA were expanded into 250 ml cultures overnight. Plasmid 
DNA was isolated from these cells using the Qiagen Maxi-prep kit according to 
manufacturer’s instructions. 
 
4.5 Transformation of competent cells 
An aliquot of competent cells TOP10 (Invitrogen) were thawed on ice for approximately 
10 minutes prior to the addition of plasmid DNA. Cells were incubated with DNA on ice 
 75 
for 30 minutes and then subjected to a heat shock for 45 seconds at 42°C. Cells were 
returned to ice for an additional 5 minutes. Then, 900 µl of LB medium was added and the 
cells were left at 37°C for further 60 minutes before plating them onto agar plates with the 
appropriate antibiotic. Plates were incubated overnight at 37°C. 
5 Constructs and plasmids  
N-terminal HA-tagged human c-Cbl WT [kindly provided by Y. Yarden - Weizmann 
Institute, Israel (137)] and mutants [c-Cbl C381A, c-Cbl I383A and c-Cbl W802* 
generated by site directed mutagenesis using the Quick Change Mutagenesis Kit 
(StrataGene), from c-Cbl WT construct] were subcloned into pBABE-puro, pGEX-6P (GE 
Healthcare) or pSLIK (Invitrogen) vectors, through restriction enzyme digestion (New 
England Biolabs) and ligation (New England Biolabs), starting from original pcDNA. 
Human Cbl-b was kindly provided to us by S. Lipkowitz [National Cancer Institute, 
Maryland, USA (237)] and cloned into pGEX-6P vector. All clones were sequence 
verified. 
EGFR mutant (Y1045/1068/1086F) was generated by site-directed mutagenesis of the 
human EGFR cDNA and sub-cloned into the pBABE-puro retroviral vector and pSLIK 
lentiviral vector. All clones were sequence verified. 
 
 
6 Cell culture 
6.1 Cell culture media 
Human epithelial cervical cancer HeLa cells were grown in GlutaMAX™-Minimum 
Essential Medium (MEM, Gibco Invitrogen), supplemented with 10% Fetal Bovine Serum 
South American (FBS SA, Invitrogen), sodium pyruvate 1 mM (Euroclone), non-essential 
aminoacids (Euroclone), and 2 mM glutamine.  
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Human epithelial cervical cancer HeLa-Oslo cells and murine fibroblastic NR6 cells were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM, Lonza), supplemented with 10% 
Fetal Bovine Serum South American (FBS SA, Invitrogen) and 2 mM glutamine.  
Phoenix helper cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% Fetal Bovine Serum South American (FBS SA, Invitrogen) and 2 
mM glutamine. 
 
6.2 Transfections 
- RNAi transfections 
RNAi transfections were performed using LipofectAMINE RNAi MAX reagent from 
Invitrogen, according to manufacturer’s instructions. Oligos for c-Cbl and Cbl-b mRNA 
silencing were designed with BLOCK-iT™ RNAi Designer from Invitrogen. Cells were 
subjected to a single (in suspension) transfection  (in the case of dynamin) or double (in 
both suspension and adhesion) transfection, treated with 10 nM RNAi oligo (except for 
clathrin KD: 24 nM RNAi oligo) and analyzed 5 days after transfection (except for 
dynamin: 2 days after transfection).  
 
- DNA transfections 
For biochemical purposes (i.e., immunoprecipitation assay), DNA transfections were 
performed using Lipofectamine reagent from Invitrogen Life Technologies, according to 
manufacturer’s instructions. Briefly, cells were plated at 80% confluency on 10 cm cell 
culture dishes. The day after cells were transfected with 5 µg DNA and 20 µl 
Lipofectamine. 24 hours after transfection cells were lysed and subjected to 
immunoprecipitation assay.  
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6.3 Retroviral and lentiviral infection 
Stable populations of HeLa cells expressing c-Cbl WT or mutant constructs (c-Cbl C381A 
and c-Cbl I383A) were generated by infecting HeLa cells using a retroviral vector. 
Retroviruses were produced by transfecting the Phoenix helper cell line with 5-10 µg of 
DNA. 48 hours after transfection, supernatant was collected and passed through a 0.45 µm 
filter. After the addition of 8 µg/ml polybrene (Hexadimethrine bromide, Sigma), the 
supernatant was added to HeLa cells plated on 10 cm cell culture dishes. Two cycles of 
infection were repeated, after which the medium was replaced with standard HeLa medium 
(see above “Cell culture media”). 48 hours after infection, selection of infected cells was 
performed by adding puromycin at a concentration of 1.5 µg/ml. NR6 cells, devoid of 
endogenous EGFR, were infected with retroviral vectors expressing WT and mutant 
human EGFR (1) using the same method as described above. NR6 clones stably expressing 
EGFR WT or mutants were generated by selection with puromycin.  
Stable clone of NR6 cells expressing human EGFR WT was infected with lentiviral 
vectors expressing c-Cbl WT or mutants (c-Cbl C381A and c-Cbl I383A). Lentiviruses 
were produced by transfecting the 293T helper cell line with 5-10 µg of DNA. 24 hours 
after transfection, supernatant was concentrated and after 24h supernatant was collected 
and passed through a 0.45 µm filter. After the addition of 8 µg/ml polybrene, the 
supernatant was added to NR6 cells plated on 10 cm cell culture dishes. Two cycles of 
infection were repeated, after which the medium was replaced with NR6 medium added of 
puromycin. 48 hours after infection, selection of infected cells was performed by adding 
gentamycin at a concentration of 400 ng /ml. 
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7 Protein procedures 
7.1 Cell lysis  
After washing with PBS 1X, cells were lysed in JS or RIPA buffer directly in the cell 
culture plates using a cell-scraper and clarified by centrifugation at 16,000 xg for 20 min at 
4ºC using a 5415 R centrifuge. Protein concentration was measured by the Bradford assay 
(Biorad) following manufacturer’s instructions. 
 
7.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Gels for resolution of proteins were made from a 30%, 37,5:1 mix of acrylamide: 
bisacrylamide (Sigma). As polymerization catalysts, 10% ammonium persulphate (APS) 
and TEMED were used. 
 
Separating gel mix 
 Gel % 
 6 8 10 
Acrylamide mix (ml) 2 2.7 3.3 
1.5 M Tris HCl, pH 8.8 (ml) 2.5 2.5 2.5 
ddH2O (ml) 5.3 4.6 4 
10% SDS (ml) 0.1 0.1 0.1 
10% APS (ml) 0.1 0.1 0.1 
TEMED (ml) 0.01 0.01 0.01 
TOTAL (ml) 10 10 10 
 
Stacking gel mix 
Acrylamide mix (ml) 1.68 
1 M Tris HCl, pH 6.8 (ml) 1.26 
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ddH2O (ml) 6.8 
10% SDS (ml) 0.1 
10% APS (ml) 0.1 
TEMED (ml) 0.01 
TOTAL (ml) 10 
 
7.3 Western Blot (WB) 
Desired amounts of proteins were loaded onto 1-1.5 mm thick SDS-PAGE gels for 
electrophoresis (Biorad). Proteins were transferred in western transfer tanks (Biorad) to 
nitrocellulose (Schleicher and Schnell) in 1X Western transfer buffer (supplemented with 
20% methanol or ethanol) at 30 V overnight or 100 V for 1 hour for small gels and at 30 V 
overnight or 0.8 A for 2 hours for large gels. Ponceau staining was used to determine the 
efficiency protein transfer onto the filters. Filters were blocked for 1 hour (or overnight) in 
5% milk or BSA in TBS supplemented with 0.1% Tween (TBS-T). After blocking, filters 
were incubated with the primary antibody, diluted in TBS-T 5% milk or BSA, for 1 hour at 
room temperature, followed by three washes of ten minutes each in TBS-T. Filters were 
then incubated with the appropriate horseradish peroxidase-conjugated secondary antibody 
diluted in TBS-T for 30 min. After the incubation with the secondary antibody, the filter 
was washed 3 times in TBS-T (10 minutes each) and the bound secondary antibody was 
revealed using the ECL method (Amersham). 
 
7.4 Anti-Ub western blot 
After SDS-PAGE, proteins were transferred on a PVDF (polyvinylidene fluoride) 
membrane (Immobilion P, Millipore), previously activated by incubation in 100% MeOH 
for 5 minutes at room temperature. Ponceau staining was avoided since it might interfere 
with antibody recognition. After transfer, filters were subjected to a denaturing treatment 
in a dedicated solution for 30 minutes at 4ºC. This treatment denatures Ub and facilitates 
 80 
the recognition of latent Ub epitopes by anti-Ub antibody resulting in intensification of the 
anti-Ub signal. After extensive washing in TBS-T buffer, filters were blocked overnight at 
4ºC in 5% BSA (dissolved in TBS-T). After blocking, filters were incubated with the 
antibodies against Ub, diluted in TBS-T 5% BSA, for 1 hour at room temperature, 
followed by 3 washes of 10 minutes each in TBS-T. Filters were then incubated with the 
anti-mouse horseradish peroxidase-conjugated secondary antibody, diluted in TBS-T 3% 
BSA, for 30 minutes at room temperature. After incubation with the secondary antibody, 
the filter was washed 3 times in TBS-T (10 minutes each) and the bound secondary 
antibody was revealed using the ECL method (Amersham). 
 
Denaturing solution 
Guanidinium Chloride 6 M 
TRIS, pH 7.4 20 mM 
PMSF (freshly added) 1 mM 
β-Mercaptoethanol (freshly added) 5 mM 
 
7.5 Immmunoprecipitation 
Lysates prepared in JS [for coimmunoprecipitiations (IP)] or in RIPA [for 
immunoprecipitation (co-IP)] buffer were incubated in the presence of specific antibodies 
(about 1-2 µg/mg of lysates) for 2 hours at 4ºC with rocking. Protein G Sepharose beads 
(Zymed) were then added, and samples were left for an additional hour at 4ºC, rocking. 
Immunoprecipitates were then washed 4 times in JS buffer or in RIPA buffer. To detect 
coimmunoprecipitation between c-Cbl, Shc and Grb2 with EGFR, EGFR was 
immunoprecipitated using an anti-EGFR antibody produced in-house [epitope: aa 1172-
1186 (Homo sapiens)]. IP and co-IP assays were performed using 300 µg and 1.5 mg, 
respectively, of fresh lysate that was subjected to IP (22,238). 
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8 Protein production and purification 
8.1 GST-fusion protein production 
Rosetta cells transformed with the indicated GST-fusion construct were picked from 
individual colonies and, used to inoculate 50 ml LB (containing ampicillin at 25 µg/ml and 
cloramphenicol at 34 ug/ml). Cultures were grown overnight at 37°C. The 50 ml overnight 
culture was diluted in 1 litre of LB and was grown at 37°C until it reached an OD of 
approximately 0.6. Then, 1 mM IPTG was added and the culture was grown either at 37°C 
for theree hours or at 18°C overnight. Cells were then pelleted at 4000 x g for 10 minutes 
at 4°C and pellets were resuspended in GST-lysis solution (20 ml/liter of bacteria). 
Samples were sonicated 5 times for 20 seconds each on ice and were pelleted at 14000 x g 
for 30 minutes at 4°C. 600 µl – 1ml of Glutathione Sepharose 4B (GE Healthcare) beads 
(1:1 slurry), previously washed 3 times with PBS and once with GST-lysis buffer, was 
added to the supernatants and samples were incubated for either 4 hours or overnight at 
4°C with rocking. Beads were washed once in PBS containing 1% triton, followed by 2 
times in PBS alone. Beads were finally resuspended in 1:1 volume of GST-maintenance 
solution and kept at -80°C. 
 
GST-lysis solution  
HEPES, pH 7.5 50 mM 
NaCl 200 mM 
EDTA 1 mM 
Glycerol  5% 
NP-40 0.1% 
Protease Inhibitors (Calbiochem) 1:500 
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GST-maintenance solution 
Tris, pH 7.4 50 mM 
NaCl 100 mM 
EDTA 1 mM 
Glycerol  10% 
DTT 1 mM 
Protease Inhibitors (Calbiochem) 1:500 
 
List of the GST-proteins used: 
- c-Cbl: full length (Homo sapiens); 
- c-Cbl C381A: full length with mutation C381A (Homo sapiens); 
- c-Cbl I383A: full length with mutation I383A (Homo sapiens); 
- c-Cbl W802*: full length with mutation W802* (Homo sapiens); 
- Cbl-b: full length (Homo sapiens); 
- Grb2: full length (Homo sapiens); 
- EGFR: aa 696-end (Homo sapiens) from Millipore, cat #14-531 
 
8.2 Cleavage of GST-fusion proteins 
GST-fusion proteins were cleaved with PreScission Protease (provided by the IFOM 
Biochemistry Unit). 1 unit of enzyme for 100 µg of fusion protein was added to the beads 
in the presence of GST-maintenance solution and incubated either overnight at 4°C or for 4 
hours at room temperature. After cleavage the supernatant containing the cleaved protein 
was collected.  
 
8.3 EGFR in vitro ubiquitination assay 
A baculovirus-produced GST-EGFR cytoplasmic tail (aa 696-end, Millipore, 250 ng) was 
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subjected to in vitro auto-phosphorylation for 1 h at 30 ºC in kinase buffer [2 mM ATP, 10 
mM MnCl2, 0.8 M (NH4)2SO4]. Phosphorylated GST-EGFR tail was then bound to 
Glutathione Sepharose 4B (GE Healthcare) beads, washed three times in YY buffer (50 
mM Hepes pH 7.5, 10% glycerol, 150 mM NaCl, 1% Triton, 1 mM EDTA, 1 mM EGTA 
plus protease/phosphatase inhibitors) and subjected to an in vitro ubiquitination reaction 
for 1 h at 30 ºC in ubiquitination buffer (250 mM Tris-HCl pH 7.6, 50 mM MgCl2, 1 M 
NaCl, 1 mM DTT, 2 mM ATP, plus ATP regeneration system, SIGMA), with the 
following amount of purified enzymes: 100 ng of E1 (purified from baculovirus), 500 ng 
of E2 (His-tagged UbcH5c/Ube2D3, purified from bacteria), 500 ng of E3 (either c-Cbl 
WT, mutants or Cbl-b, purified from bacteria), 1 µg of Ub (SIGMA), with or without Grb2 
(purified from bacteria). Beads were then washed four times in YY buffer 0.1% SDS and 
eluted in Laemmli buffer. Enzymes were purified as described (239). 
 
 
9 Assays with 125I-EGF  
9.1 Receptor internalization assays with 125I-EGF  
Cells were serum starved for at least 4 hours and then incubated at 37°C in the presence of 
125I-EGF in binding buffer (MEM or DMEM, BSA 0.1%, Hepes pH 7.4 20 mM). The 
concentration of radiolabelled EGF used in the assays was the following: 
Low Dose EGF internalization 125I-EGF: 1 ng/ml 
High Dose EGF internalization 125I-EGF: 30 ng/ml 
 
After 2, 4, 6 minutes (for HeLa cells) or 4,8, 12 minutes (for NR6 cells) of EGF treatment, 
cells were washed 3 times in PBS, and then incubated for 5 minutes at 4°C in 300 µl of 
acid wash solution, pH 2.5 (acetic acid 0.2 M, NaCl 0.5 M). The solution was then 
removed from the cells and the radioactivity present in it was measured. This sample 
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represents the amount of 125I-EGF bound to the receptor on the cell surface. Cells were 
then lysed with 300 µl of a solution containing 1 M NaOH. This sample represents the 
amount of internalized 125I-EGF. The unspecific binding was measured at each time point 
in the presence of an excess of non-radioactive EGF (300X). After correction for non-
specific binding, the ratio between internalized and surface-bound radioactivity was 
determined for each time point. This data was used to obtain the internalization curves (x-
axis time in min, y-axis 125I-EGF Internalized/bound). Internalization rate constants were 
extrapolated from the internalization curves and correspond to slopes of the best-fitting 
curves. 
 
9.2 Measurement of the number of EGFRs at the cell surface by saturation binding 
with 125I-EGF  
Cells were serum starved in binding buffer (MEM or DMEM, BSA 0.1%, Hepes pH 7.4 20 
mM) for at least 4 hours and then incubated in the presence of 5 ng/ml of 125I-EGF. To 
reach the final concentration of 100 ng/ml, unlabeled EGF was added to the mix. Samples 
were cooled on ice for 30 minutes and incubated at 4°C with mix containing 125I-EGF. 
After 6 hours, cells were washed 3 times in PBS, and then were lysed with 300 µl of a 
solution containing 1 M NaOH. This sample represents the amount of 125I-EGF bound at 
equilibrium, which is dependent on the number of EGFRs on the cell surface. The 
unspecific binding was measured at each time point in the presence of an excess of non-
radioactive EGF (300X). After correction for non-specific binding, the assay provides the 
quantitative measurement of the number of EGFRs for each well. By counting the number 
of cells plated in each well, this assay allows the determination of the number of surface 
EGFRs/cell. 
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10 Immunofluorescence studies 
Cells were plated on glass coverslips pre-incubated with 0.1% gelatin in PBS at 37°C for 
30 minutes. Cells were fixed in 4% paraformaldehyde (in 1X PBS) for 10 minutes, washed 
with PBS and permeabilized in 0.1% Triton X-100, BSA 0.2% in 1X PBS for 8 minutes at 
room temperature. To prevent non-specific binding of the antibodies, cells were then 
incubated with 1X PBS in presence of 2% BSA for 30 minutes at room temperature. Next, 
cells were incubated for 1 hour with primary antibody in 1X PBS in presence of 0.2% BSA 
(anti-HA Babco or anti-EGFR in-house-made, or c-Cbl BD), washed 3 times with 1X PBS 
and incubated for 30 minutes with fluorescently labeled secondary antibodies (Amersham). 
After 3 washes with PBS, nuclei were DAPI-stained for 5 minutes and washed again 3 
times with 1X PBS. Coverslips were immediately mounted with moviol and examined 
under a wide-field fluorescence microscope (Olympus). Images were further processed 
with the ImageJ software. To detect only surface EGFR  (anti-EGFR Ab-1, Calbiochem) 
permeabilization step was avoided.  
 
11 FACS (Fluorescence-activated cell sorting) analysis 
Cells were washed in PBS and resuspended in PBS 0.5 ml and then added formaldehyde 
2% 0.5 ml for 20 minutes on ice. They were subsequerntly washed in PBS in presence of 
1% BSA and to prevent non-specific binding of the antibodies, resuspended in PBS BSA 
5% and incubated for 30 minutes at room temperature. Next, cells were incubated for 1 
hour with primary antibody in 1X PBS in presence of 1% BSA (anti-EGFR antibody that 
recognizes the extracellular domain of the receptor), washed in PBS in presence of 1% 
BSA and incubated for 1 hour with fluorescently labeled secondary antibodies 
(Amersham). After washing with PBS, cells were ready to be analysed with FACScanto II 
(Becton Dickinson). 
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12 Densitometry and statistical analysis 
Quantification of blot was performed with Photoshop. Error bars in the plots represent the 
standard deviation of the mean. All statistical analyses were performed using Excel. 
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Aim of the project 
The role of ubiquitination in EGFR endocytosis and trafficking has been extensively 
studied [reviewed in (150)]. The family of E3 ubiquitin ligases involved in EGFR 
ubiquitination is the family of Cbl proteins (137,161,162,174), which are recruited to the 
active/phosphorylated receptor leading to its ubiquitination and endocytosis 
(97,174,222,234,240). 
Although ubiquitination mediated by c-Cbl is known to be critical for targeting 
EGFR to lysosomal degradation, the role played by c-Cbl at the early EGFR internalization 
steps still needs to be elucidated. This is a very complex question to answer since several 
factors hinder the study of the role of Cbl proteins in EGFR internalization. First, EGFR 
can be internalized through different pathways, such as CME and NCE, with different 
ubiquitin requirements. Indeed, EGFR ubiquitination is not essential for CME (1,2), while 
it is absolutely required for NCE (1,226). Second, c-Cbl can ubiquitinate other endocytic 
substrates besides EGFR and this might represent an important regulatory mechanism along 
the endocytic pathway (3). Third, in addition to its role as E3 ligase, c-Cbl also functions as 
an adaptor molecule by recruiting several proteins involved in the early phases of CME (3). 
Having these factors in mind, we developed a multi-approach experimental plan that 
allowed us to overcome some of them and to further investigate the role of Cbl proteins in 
EGFR ubiquitination and internalization.  
The first aim of this study was, thus, to understand the connection between Cbl 
proteins and EGFR ubiquitination. To this aim, we analyzed the differential/redundant 
effect of Cbl proteins in EGFR ubiquitination by performing RNAi-based functional assays 
in different cellular model systems. In particular, we have: i) ablated c-Cbl and/or Cbl-b 
(the two Cbl proteins expressed in our cell models) and analyzed their differential or 
redundant effect on EGFR ubiquitination; ii) performed KD of c-Cbl/Cbl-b with known 
endocytic players and performed EGFR internalization assays, in order to clarify the role of 
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Cbl proteins in EGFR CME versus NCE (to gain further insight into the process the 
requirement of Grb2 in EGFR ubiquitination and endocytosis was also assessed); iii) 
analyzed the impact of c-Cbl/Cbl-b KD on the ubiquitination of endocytic adaptors. 
Our second aim was to study the molecular mechanisms underlying the role of c-
Cbl in EGFR internalization. To this end, we undertook a genetic approach and performed 
reconstitution experiments with c-Cbl WT or mutants defective in E3 ligase activity to 
clarify whether the role of c-Cbl in EGFR internalization is mediated via its E3 ligase or 
adaptor function.  
Our final aim was to dissect the molecular requirements for the EGFR 
ubiquitination reaction. To achieve this goal, we set-up an in vitro EGFR ubiquitination 
assay with all purified components, which allowed us to confirm the essential role of Grb2 
in c-Cbl-mediated EGFR ubiquitination. In future studies, we expect to employ this in vitro 
assay to better characterize c-Cbl E3 ligase activity in terms of processivity and chain 
specificity, and to unveil possible differences with Cbl-b. 
From this study, we expect results to provide a deeper understanding of possible 
differential role of c-Cbl and Cbl-b in the endocytic pathway of the EGFR. 
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Results 
1 Experimental set up 
We designed an experimental plan that allowed us to investigate the role of Cbl proteins in 
EGFR endocytosis. We used two cellular model systems: HeLa cells express substantial 
levels - although within the physiological range - of endogenous EGFR (about 200 000 
receptors/cell) and have been extensively characterized by our group and others for EGFR 
ubiquitination and endocytosis (92,97); in addition we chose another model that does not 
express endogenous EGFR and was therefore enginereed to express the WT form or 
mutant of the receptor [NR6 cells, fibroblast derivative of NIH devoid of endogenous 
EGFR (241)]. The use of these two different cell lines allowed us to highlight a different 
importance of Cbl proteins according to the cellular context analysed. Importantly, it was 
crucial to our study to be able to characterize the involvement of Cbl proteins both in 
EGFR CME and NCE. Our experimental set up was thus based on 125I-EGF internalization 
assays that were performed in highly controlled conditions that allowed us to study these 
two mechanisms independently, as described below. 
1) Since in our cellular models (HeLa and NR6 cells) EGFR can be internalized either by 
CME or by NCE (1,226) depending on ligand concentration, we performed experiments 
using two doses of EGF: 
− Non-saturating concentration of EGF (1 ng/ml) 
At a non-saturating dose, only CME - and not NCE - is active.  Thus, by using 1 
ng/ml of EGF we ensure that any observed effects can be directly and specifically 
ascribed to the clathrin-mediated internalization pathway. Indeed, at this ligand 
concentration, silencing of CHC causes, approximately, an 80% inhibition of 
EGFR internalization (13,92) and see also Figure 19B, Figure 20B left panels). The 
residual (remaining 20%) EGFR internalization is mediated by an alternative 
endocytic pathway that is insensitive to clathrin depletion. Indeed, we have 
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observed that this residual EGFR internalization is also unaffected by filipin 
treatment (a cholesterol-interfering compound) or dynamin KD. Thus, this residual 
internalization is not NCE, but rather a third kind of internalization pathway used 
by EGFR, which we have shown to be mostly kinase independent (226). 
− High dose of EGF (30 ng/ml) 
In this experimental condition both CME and NCE pathways are active. In order to 
activate only NCE, we performed CHC KD, alone or in combination with the gene 
of interest. For high EGF doses, the kinetic parameter might not measure the actual 
endocytic rate constant, since at this dose bound counts might not remain constant 
over time. For this reason, instead of Ke (constant rate), we use the more 
appropriate term “observed Ke” [Ke obs, see also (242)], when describing the 
kinetics parameter at high EGF doses.  
Internalization assays were performed at 2, 4 and 6 minutes for HeLa cells and 4, 8 and 12 
minutes for NR6 cells. From the kinetics, we calculated the Ke. 
2) The ligand was applied to the cells in continuum, without any ligand pre-binding on ice. 
This represents a more physiological situation and prevents artifacts that could mask or 
enhance internalization defects.  
3) Both HeLa cells and NR6 cells stably expressing EGFR WT or mutants were used as 
cell model system. NR6 clones expressing EGFR WT or mutants were generated. EGFR 
levels were assessed through western blot (WB) analysis, immunofluorescence (IF), 
fluorescence-activated cell sorting (FACS) analysis and iodinated assays in order to select 
homogeneous EGFR-expressing clones with similar levels to HeLa cells. 
4) All KD were performed transiently and at least 2 different oligos against each target 
were used with similar results. Reconstitution experiments were performed both in HeLa 
and NR6 cells. HeLa cells were infected with stable retroviral vectors expressing different 
forms of c-Cbl (WT or mutants) and, due to the heterogeneity of the bulk population, 
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homogeneous clones were selected, by analyzing c-Cbl expression through IF analysis 
(Figure 24). NR6 cells expressing either EGFR WT or TripleF/3F (Y1045/1068/1086F) 
were infected with the doxycycline-inducible vector pSLIK (243) to express 
homogenously c-Cbl WT or mutants, upon doxycycline treatment (Figure 26). 
5) Cell surface EGFR was quantified in KD cells using the 125I-EGF saturation-binding 
assay. Silencing of Cbl proteins did not alter the cell surface number of EGFR (data not 
shown). This result allowed us to exclude any involvement of Cbl proteins in EGFR 
biosynthesis/delivery to the PM, and in basal receptor turnover. Moreover, it also allowed 
us to exclude that differences in EGFR internalization rates are due to different starting 
numbers of surface EGFRs in KD cells with respect to control cells.  
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2 c-Cbl is the major E3 ligase involved in EGFR ubiquitination in HeLa 
cells 
Previous studies have demonstrated that EGFR ubiquitination is essential for targeting the 
receptor to lysosomal degradation, while it plays a non-essential role at the early 
internalization steps (1,2,148). In contrast, c-Cbl seems to have a crucial role also at this 
initial stage (234). The situation is complicated by the existence of multiple entering 
pathways dependent on cell context and on the experimental conditions used.  
In order to depict a clearer picture of the role of Cbl proteins in EGFR 
ubiquitination and endocytosis (CME vs NCE), we firstly analysed the phenotype of Cbl 
proteins silencing in HeLa cells. Since the Cbl family consists of three members, c-Cbl, 
Cbl-b, and Cbl-c (see Introduction), we first determined their expression at the mRNA 
(messenger RNA) and/or protein level in our cellular model system, HeLa cells (Figure 
16A). As depicted in the figure, CBL-C expression is undetectable, thus it will be not 
considered in our further experiments; on the contrary, C-CBL is 8-fold greater compared 
to CBL-B mRNA. 
We initially investigated the involvement of c-Cbl and Cbl-b in EGFR 
ubiquitination by ablating the expression of these two proteins, alone or in combination in 
HeLa cells, using RNA interference technique (Figure 16B). Single and double c-Cbl/Cbl-
b KD cells were stimulated with high dose of EGF for 2 minutes and, after EGFR 
immunoprecipitation, the EGFR ubiquitination levels were analysed. In HeLa cells (Figure 
16C), we observed that the KD of c-Cbl dramatically decreased EGFR ubiquitination to 
less than 10% of residual signal, while Cbl-b KD cells showed only a minor -if any- 
reduction compared to control cells (Figure 16C). When combined to c-Cbl KD, Cbl-b KD 
only slightly reduced EGFR ubiquitination. These data suggest that c-Cbl is the major E3 
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ligase involved in EGFR ubiquitination at early time points in HeLa cells, although Cbl-b 
might play an additional role in this process.  
Since ubiquitination has an established role in targeting EGFR for lysosomal 
degradation at late stages of endocytosis, we extended our experimental analysis of the 
effects of c-Cbl/Cbl-b KD on EGFR ubiquitination to later time points. To this aim, we 
chose to perform an ELISA (Enzyme-Linked ImmunoSorbent Assay)-based assay that 
allows quantitative measurements of EGFR ubiquitination for a longer period of time. 
After ablation of c-Cbl and Cbl-b, alone or in combination, HeLa cells were stimulated 
with high dose of EGF for different periods of time (from 0 to 180 minutes). We observed 
that, throughout the analysed time points, EGFR ubiquitination was almost completely 
impaired in the absence of c-Cbl (~90% reduction; Figure 16D). A subsequent 10% 
reduction in EGFR ubiquitination was further achieved with the KD of Cbl-b. These 
results suggest that c-Cbl is the major E3 ligase involved in EGFR ubiquitination even at 
late steps of endocytosis in HeLa cells, and that Cbl-b contributes to this process only to a 
minor extent.  
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Figure 16 Role of Cbl proteins in EGFR ubiquitination. (A) Expression of C-CBL, 
CBL-B and CBL-C genes were assessed by qPCR analysis. Ct values and fold change are 
reported. The mRNA levels of the different genes were normalized to the housekeeping 
gene 18S and C-CBL was used as reference gene. (B) HeLa cells were silenced for c-Cbl 
and Cbl-b. Protein expression was determined by immunoblotting using specific 
antibodies, as indicated. Tubulin was used as a protein loading control. (C) In vivo EGFR 
ubiquitination. HeLa cells, subjected to KD as indicated, were serum starved o.n. (-) and 
then stimulated (+) with high dose of EGF (100 ng/ml) for 2 minutes. EGFR was 
immunoprecipitated with anti-EGFR antibodies and ubiquitination was detected through a 
specific antibody against ubiquitin (P4D1, Santa Cruz). Levels of immunoprecipitated 
EGFR were determined with anti-EGFR antibodies. Results are representative of more 
than three experiments. (D) Quantitative EGFR ubiquitination analysis at late time points. 
HeLa cells were silenced for c-Cbl and Cbl-b (single or in combination) and serum starved 
o.n. At the indicated time points, cells were stimulated with high dose of EGF (100 ng/ml). 
Samples were subjected to ELISA assay using anti-Ub (FK2) as detecting antibody. 
Absolute level of EGFR ubiquitination is displayed as arbitrary units. 
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3 Interplay between c-Cbl and Grb2 in EGFR ubiquitination 
The recruitment of c-Cbl to the EGFR follows a cooperative behaviour in which two binding 
sites are needed: c-Cbl can directly bind to the EGFR through the interaction involving its 
TKB domain and the phospho-tyrosine (pY)1045 in the cytoplasmic tail of the receptor or it 
can be recruited to the EGFR via the adaptor protein Grb2 that is composed of one SH2 and 
two SH3 domains; indeed, the proline rich region in the C-terminus of c-Cbl interacts with 
SH3 domain of Grb2, which in turn binds to the pY1068/1086 of the receptor through its 
SH2 domain (Figure 17A). 
In order to initially clarify the importance of Grb2 in the system, we silenced Grb2 
and analysed the effects in EGFR ubiquitination. As shown in Figure 17B, upon Grb2 KD, 
EGFR ubiquitination was significantly reduced in stimulated cells, suggesting that Grb2 is a 
crucial player in this process. 
To fully understand the interplay of Grb2/c-Cbl in EGFR ubiquitination and to unveil 
possible differences in the E3 ligase activity of the two Cbl proteins, we reconstituted the 
EGFR ubiquitination reaction in an in vitro ubiquitination assay. To this aim, we purified 
EGFR protein from baculovirus and induced the auto-phosphorylation in vitro of the 
intracellular domain of purified EGFR to use it as substrate in the ubiquitination reaction. In 
this in vitro ubiquitination assay, c-Cbl was used as E3 ligase and UbcH5c as E2, in presence 
or absence of Grb2. As seen in Figure 17C, we managed to ubiquitinate EGFR in vitro and 
found that the level of ubiquitination was maximal when Grb2 was present, confirming a 
strong requirement of Grb2 for efficient catalysis. On the contrary, c-Cbl alone is not very 
efficient, despite the efficient phosphorylation of its direct binding site. In the same assay, 
Cbl-b showed a Grb2-dependent ubiquitination activity on EGFR similar to the one observed 
in c-Cbl, (Figure 17D). These data suggest that the two Cbl proteins ubiquitinate the EGFR 
via a similar mechanism at least in this in vitro assay. However, we cannot exclude that c-Cbl 
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and Cbl-b proteins have different processivity or specificity towards ubiquitin chains. Further 
studies are required to better clarify this point. 
 
 
Figure 17 Recruitment of Grb2 for complete EGFR ubiquitination. (A) Modelling of 
c-Cbl recruitment to the EGFR (schematic representation of EGFR cytoplasmic tail). c-Cbl 
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is recruited to the activated EGFR directly through pY1045 and indirectly through Grb2 to 
pY1068/1086. The stable recruitment of c-Cbl via both pY-sites leads to full EGFR 
ubiquitination. (B) HeLa cells were subjected to Grb2 KD or transfection with a scramble 
oligo. Lysates were stimulated with EGF for two minutes as indicated and subjected to 
IP/IB as shown. (C) In vitro ubiquitination assay with c-Cbl as E3 ligase. GST-EGFR 
cytoplasmic tail was subjected to in vitro autophosphorylation reaction. Then, it was 
subjected to ubiquitination reaction in the presence of ubiquitin, bacterially purified E1, 
UbcH5c as E2, c-Cbl as E3 and ATP regeneration system, with or without Grb2 (ten times 
c-Cbl in molarity). Results from control reactions performed without EGFR or without E2 
are shown. Immunoblotting was as indicated. Results are representative of more than three 
experiments. (D) In vitro ubiquitination assay with Cbl-b as E3 ligase. GST-EGFR 
cytoplasmic tail was subjected to in vitro autophosphorylation and ubiquitination reaction 
as described in (C) with exception of the E3 in the reaction mixture being Cbl-b (500 ng) 
instead of c-Cbl. Results from control reactions performed with EGFR not phosphorylated 
(lane 2) or without either E2, E3 or EGFR are shown. Immunoblotting was as indicated. 
Results are representative of three experiments.  
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4 Role of Cbl proteins and Grb2 in EGFR CME and NCE 
In order to understand a possible specific role of c-Cbl in EGFR internalization, we 
performed c-Cbl KD in presence or in absence of clathrin and dynamin and we performed 
internalization assays at low and high doses of EGF. At low EGF doses, a condition where 
only CME is active, c-Cbl KD cells displayed a decrease of 30% of the EGF internalization 
rate (Figure 18B, left panel), a result comparable to what other groups have already reported 
(2). Furthermore, double KDs (c-Cbl/clathrin or dynamin KD) did not result in any 
worsening of the single clathrin or dynamin KD phenotypes (Figure 18B, left panel). This 
result showed that, although not being completely essential, c-Cbl plays an important role in 
CME. At high EGF concentration, where both CME and NCE are active, c-Cbl KD led to an 
important impairment (about 30-40%) in EGF internalization rate (Figure 18B, right panel). 
In addition, while in a dynamin KD background c-Cbl KD did not worsen the defect of the 
individual dynamin KD, double c-Cbl/clathrin KD caused a complete reduction in the EGF 
internalization rate to dynamin KD-induced levels (Figure 18B, right panel). These data 
show that c-Cbl is essential for EGFR internalization via NCE, which is compatible with the 
fact that the EGFR ubiquitination is required for NCE (1). From these data, we can conclude 
that NCE is completely dependent on c-Cbl, while EGFR CME displays only a partial 
dependency on this E3 ligase.   
 
 99 
 
Figure 18 c-Cbl is involved both in CME and in NCE. (A) HeLa cells were silenced for 
c-Cbl, clathrin and/or dynamin. Protein expression was determined by immunoblotting 
using specific antibodies, as indicated. Tubulin was used as a protein loading control. 
Results are representative of more than three experiments. (B) 125I-EGF internalization 
kinetics in control HeLa cells or upon different KD as indicated, at low EGF (1 ng/ml) (left 
panel) or high dose of EGF (30 ng/ml) (right panel). Results are expressed as 
internalization rate constants (Ke or Kobs) and are the mean of triplicate experiments. 
 
Grb2 was previously found to be essential for EGFR CME through siRNA depletion 
of Grb2, which substantially reduces internalization of EGFR in different cell lines 
(148,244). To confirm the essential role of Grb2 in EGFR CME in our model system, we 
performed Grb2 KD, alone or in combination with clathrin and dynamin KD (Figure 19A) 
and performed EGFR internalization assay. We confirmed the essential role of Grb2 in 
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EGFR clathrin-mediated internalization since we observed a complete impairment of EGFR 
internalization upon Grb2 KD, comparable to the one observed in clathrin KD cells (Figure 
19B, left panel). Importantly, we were also able to establish an essential role of Grb2 in 
EGFR NCE, since Grb2 KD, alone or in combination with clathrin KD (Figure 19B, right 
panel) reduced internalization kinetics to the levels observed in dynamin KD cells. 
 
 
Figure 19 Role of Grb2 in EGFR internalization. (A) HeLa cells were silenced for 
Grb2, clathrin and/or dynamin. Protein expression was determined by immunoblotting 
using specific antibodies, as indicated. Tubulin was used as a protein loading control. 
Results are representative of more than three experiments. (B) 125I-EGF internalization 
kinetics in control HeLa cells or upon different KD as indicated, at low EGF (1 ng/ml) (left 
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panel) or high dose of EGF (30 ng/ml) (right panel). Results are expressed as 
internalization rate constants (Ke or Kobs) and are the mean of triplicate experiments.  
 
At this point we wondered whether the two members of Cbl family could act 
differently in EGFR CME and NCE. Thus, we transiently ablated the two members of Cbl 
family expressed in HeLa cells in presence or in absence of clathrin (Figure 20A). To this 
aim, we performed internalization assays upon c-Cbl and/or Cbl-b KD at low and high dose 
of EGF. As shown in Figure 20B, Cbl-b KD did not have any effect in EGFR internalization 
either at low or high EGF doses. In addition, the combined silencing of c-Cbl and Cbl-b did 
not further decrease the internalization defect observed in c-Cbl KD cells. These data suggest 
that, in HeLa cells, c-Cbl plays an important role in EGFR internalization via CME (not 
essential) and NCE (essential), while Cbl-b seems not involved at this step. Thus, in this 
cellular system, the two Cbl proteins seem to play a non-redundant role in EGFR 
internalization.  
 
 102 
 
Figure 20 c-Cbl and Cbl-b have different impact on EGFR internalization in HeLa 
cells. (A) HeLa cells were silenced for c-Cbl, Cbl-b and/or clathrin. Protein expression was 
determined by immunoblotting using specific antibodies, as indicated. Tubulin was used as 
a protein loading control. Results are representative of more than three experiments. (B) 
125I-EGF internalization kinetics in control HeLa cells or upon different KD as indicated, at 
low EGF (1 ng/ml) (left panel) or high dose of EGF (30 ng/ml) (right panel). Results are 
expressed as internalization rate constants (Ke or Kobs) and are the mean of triplicate 
experiments. 
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5 The role of c-Cbl in CME is independent from EGFR ubiquitination  
As we have already discussed, differently from NCE, EGFR ubiquitination seems to be 
non-essential for clathrin-mediated endocytosis (1,2,148). Thus, we were interested in 
investigating the role of c-Cbl in CME. To this aim, we took advantage of NR6 cells 
infected with retroviral vector expressing WT EGFR or a mutant form of EGFR (3F). This 
mutant carries the three binding sites of c-Cbl (both direct and indirect) mutagenized into 
phenylalanine (Y1045/1068/1086F) (Figure 21A). Of note, 3F mutant cannot enter the cell 
via NCE, while it can still be internalized through CME, displaying only minor defects in 
this clathrin-dependent internalization pathway (226). Using 125I-EGF saturation binding 
assays and WB analysis (Figure 21B,C), we selected NR6 clones whose expression of 
EGFR surface levels was comparable to HeLa cells (about 200 000 receptors/cell). Such 
clones presented also homogenous surface EGFR expression as assessed by IF and FACS 
analysis (Figure 21D, E).  
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Figure 21 Characterization of NR6 cells expressing either EGFR WT or EGFR 3F. 
(A) Scheme of the Y-to-F mutants used in this study. The intracellular domain comprising 
the kinase domain and the C-terminal tail of the EGFR is shown with the positions of 
relevant residues. Mutagenized residues are indicated in red. (B) NR6 cells stably 
expressing EGFR WT or the indicated mutant were analysed by 125I-EGF saturation 
binding and the number of surface receptors was measured. Data are expressed as surface 
EGFR/cell. (C) EGFR levels of the studied samples were determined by immunoblotting 
using specific antibodies, as indicated. Tubulin was used as a protein loading control. (D) 
The homogeneity of the selected clones was analyzed through IF; the EGFR was detected 
through an in-house antibody detecting the extracellular domain of the EGFR. Thus, no 
permeabilization was performed. The primary antibody was revealed through anti-mouse 
Cy3 secondary antibody. (E) FACS analysis of the selected clones was performed to 
further validate the homogeneity of the clones. The primary antibody used was the same as 
the one used for IF and therefore no permeabilization was performed. 
 
We started by determining the expression of c-Cbl and Cbl-b in NR6 cells. As 
observed in Figure 22A, NR6 cells showed similar levels of C-CBL and CBL-B, displaying 
only a lower expression of CBL-B compared to C-CBL (about 30%). We then 
characterized the 3F mutant for its ubiquitination level compared to the WT form in the 
presence or absence of Cbl proteins. We analysed the expression of Cbl proteins upon KD 
by WB (Figure 22B). Upon EGF stimulation, EGFR WT showed a strong increase in 
EGFR ubiquitination, which slightly decreased upon c-Cbl and Cbl-b single KD (Figure 
22C); only when the two proteins were simultaneously ablated, EGFR ubiquitination 
dramatically decreased (Figure 22C). Importantly, the mutant EGFR 3F showed a great 
decrease in EGFR ubiquitination by more than 95% compared to WT receptor and ablation 
of c-Cbl/Cbl-b in this sample induced only a slight reduction of the already low EGFR 
ubiquitination levels. Note that the receptor levels are immunoprecipitated less efficiently 
in the last sample (NR6 EGFR 3F, c-Cbl/Cbl-b KD). From these data we can conclude that 
EGFR 3F is ubiquitin-defective and could represent a good tool to study the impact of 
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EGFR ubiquitination in CME. Of note, this mutant has only a minor defect in CME 
[Figure 22D and (226)], confirming that EGFR ubiquitination is not essential for CME. 
To understand whether the internalization of the receptor in the 3F mutant could still 
depend on Cbl proteins, we performed an internalization assay at low EGF concentration, 
upon c-Cbl and Cbl-b KD, both singularly and in combination. The combined silencing of c-
Cbl and Cbl-b reduced by 50% EGFR internalization, while the single KD did not have any 
effect, thus suggesting a redundant role of these two proteins in EGFR CME (Figure 22D). 
The EGFR WT and 3F displayed a similar behaviour since internalization was dependent on 
c-Cbl/Cbl-b in both cases and to the same extent. This result suggests that c-Cbl/Cbl-b have a 
role in EGFR internalization independently on receptor ubiquitination.  
Since in EGFR 3F the major c-Cbl binding sites (direct and indirect) are mutated, we 
did not expect c-Cbl to be recruited to the EGFR 3F. Indeed, results from a co-
immunoprecipitation experiment showed that while c-Cbl was recruited to the EGFR WT 
upon EGF stimulus, it did not stably associate with the 3F mutant (Figure 22E). On the 
contrary, Grb2 binding was only partially affected (Figure 22E), possibly due to the presence 
of other indirect binding sites. Indeed, Grb2 can interact through its SH3 domain to Shc, 
which, in turn, binds with its SH2 to the pY1173 on the EGFR.  This site might be 
responsible for the Grb2 recruitment. We cannot exclude that c-Cbl is recruited via Grb2 to 
this site in an unstable/low affinity interaction (not detected by coIP). Nevertheless, our data 
show that c-Cbl is required for EGFR internalization even if it is not stably recruited to the 
receptor. Altogether, these data suggest that the ubiquitination of the receptor itself is not 
essential for CME and that Cbl proteins are required, either because they ubiquitinate other 
substrates involved in EGFR internalization or because they can act as endocytic adaptors in 
CME. 
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Figure 22 Role of Cbl proteins in EGFR ubiquitination and internalization in NR6 
cells. (A) Levels of C-CBL and CBL-B were assessed by qPCR analysis. Ct values are 
reported, and the mRNA levels of the different genes were normalized on the 
housekeeping gene 18S. C-CBL was used as reference gene. (B) NR6 cells expressing 
either EGFR WT or EGFR 3F were silenced for c-Cbl and Cbl-b, singularly or in 
combination. Levels of c-Cbl and Cbl-b expression were determined by immunoblotting 
using specific antibodies, as indicated. Tubulin was used as a protein loading control. (C) 
In vivo EGFR ubiquitination. NR6 cells EGFR WT or 3F, subjected to KD as indicated, 
were serum starved o.n. (-) and then stimulated (+) with high dose of EGF (100 ng/ml) for 
2 minutes. EGFR was immunoprecipitated with anti-EGFR antibodies and ubiquitination 
was detected through a specific antibody against ubiquitin (P4D1, Santa Cruz). Levels of 
precipitated EGFR were determined with anti-EGFR antibodies. Results are representative 
of three experiments.  (D) 125I-EGF internalization in EGFR WT and EGFR 3F NR6 cells, 
upon KD of Cbl proteins. EGF internalization was measured in the presence of 125I-EGF 1 
ng/ml at initial time points (4, 8 and 12 min). Internalization constants were extrapolated 
from the internalization curves and correspond to the slopes of the best-fitting curves. 
Error bars indicate standard deviation calculated on two independent experiments. (E) 
Coimmunoprecipitation of c-Cbl, Shc and Grb2 with EGFR. NR6 cells expressing EGFR 
WT or EGFR 3F were serum starved o.n. (-) and stimulated with 100 ng/ml of EGF for 2 
minutes (+). EGFR was immunoprecipitated with anti-EGFR antibodies and c-Cbl, Shc 
and Grb2 levels were detected by using specific antibodies, as indicated. 
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6 RING finger mutations abrogate E3 ligase activity of c-Cbl 
Due to its complex structure, c-Cbl has different interactors involved in multiple cellular 
processes. Indeed, it can work both as E3 ligase and adaptor protein (see introduction section 
5.1). To uncover a possible role of c-Cbl as E3 ligase involved in EGFR internalization, we 
decided to investigate whether c-Cbl mutants in the RING finger domain lacking E3 ligase 
activity could reconstitute the EGFR internalization defect induced by the ablation of Cbl 
proteins, both in Hela and NR6 cells.  
We generated two c-Cbl mutants: c-Cbl C381A, which carries a mutation previously 
shown to abolish the E3 ligase activity of c-Cbl and that possibly disrupts the RING finger 
domain (245); and c-Cbl I383A, carrying a mutation described by Brzovic and colleagues 
able to impair the E3 ligase activity of Brca1 without disrupting the structure of the RING 
finger (107) (Figure 23A). In Brca1, the mutation of this aminoacid (Ile26) neither disrupts 
the overall structure of the RING domain, nor prevents interactions with other protein 
partners, but the integrity of this residue is critical for E3 ligase activity and can represent a 
general determinant for E2 recognition and binding (107). Through the in vitro ubiquitination 
assay that we have set up and previously described (Figure 17B), we observed that both 
mutants were unable to ubiquitinate EGFR, both in absence or presence of the adaptor 
protein Grb2, even though their binding to the activated EGFR was not affected (Figure 
23B). 
We first analysed the impact of these two mutants on EGFR ubiquitination in an 
overexpression system. Indeed, we transiently transfected HeLa cells with vectors carrying 
either c-Cbl WT or the RING finger mutants or the negative control v-cbl (a truncated viral 
form of c-Cbl). The constructs were almost equally transfected as shown from IB of total cell 
lysate in Figure 23C. Cells were serum starved o.n. and stimulated with high dose of EGF for 
2 minutes; we immunoprecipitated endogenous EGFR and analysed its ubiquitination by 
WB. As shown in Figure 23C, as expected, the overexpression of the WT form increased 
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EGFR ubiquitination, compared to endogenous, while the C381A mutant strongly reduced 
the endogenous EGFR ubiquitination. Thus, the C381A clearly shows an impaired E3 ligase 
activity and works also as dominant negative towards the endogenous c-Cbl. Overexpression 
of the I383A mutant seems to cause an increase (and not a reduction) of EGFR ubiquitination 
compared to the endogenous, although it does not reach the level of c-Cbl WT. This result 
was also confirmed using a different cell system that does not express EGFR (phoenix cells) 
where we cotransfected vector expressing EGFR and the above-cited vectors carrying 
different forms of c-Cbl (Figure 23D).  
This result appears in contrast with the in vitro data, where both C381A and I383A 
mutants behaved equally and appear to be “catalitically dead” (see discussion, section 4).  
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Figure 23 Characterization of c-Cbl E3 ligase mutants. (A) Schematic representation of 
c-Cbl structure with the domains that compose the protein. In red are indicated the residues 
within the RING domain that were mutagenized into alanine. (B) In vitro ubiquitination 
assay with either c-Cbl WT, C381A or I383A as E3 ligases. GST-EGFR cytoplasmic tail 
was subjected to in vitro autophosphorylation and ubiquitination reaction as described in 
Figure 17B with exception of the E3 in the reaction mixture. The control reactions with 
EGFR not phosphorylated or without either E2 or E3 or EGFR are shown. Immunoblotting 
was as indicated. Results are representative of two experiments. (C) In vivo EGFR 
ubiquitination. HeLa cells were transiently transfected with either control vector or 
different forms of c-Cbl (WT, C381A, I383A). Cells were serum starved 8 hours (-) and 
then stimulated (+) with high dose of EGF (100 ng/ml) for 2 minutes. EGFR was 
immunoprecipitated with anti-EGFR antibodies and ubiquitination was detected through a 
specific antibody against ubiquitin (P4D1, Santa Cruz). Levels of precipitated EGFR were 
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determined with anti-EGFR antibodies. Results are representative of three experiments. 
Levels of transfection were detected by using specific antibodies as indicated. (D) In vivo 
EGFR ubiquitination. Phoenix cells were transiently transfected with vector expressing 
EGFR and different forms of c-Cbl. Samples were treated as described in (C). 
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To better understand what is going on in a more physiological situation (i.e. w/o 
overexpression), we performed reconstitution experiments with E3 ligase mutants upon KD 
of endogenous c-Cbl. To this aim, we generated stable clones of HeLa cells expressing c-Cbl 
WT, c-Cbl C381A and c-Cbl I383A at the endogenous level. These clones were selected and 
characterized, through WB analysis and immunofluorescence for expression level and 
homogeneity (Figure 24).  
 
 
 
Figure 24 Characterization of HeLa clones expressing c-Cbl WT, C381A and I383A. 
(A) WB analysis of different clones by immunoblotting with specific antibody, as 
indicated. Tubulin was used as a protein loading control. (B) IF analysis of the selected 
clones (in red rectangle) to validate the homogeneity. 
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To perform c-Cbl ablation, we used RNAi oligos that target the 3’-UTR (untranslated 
region) of the mRNA without targeting the exogenous cDNA constructs (transgene). The 
efficiency of the KD was assessed by qPCR analysis using oligos which recognize the 3’-
UTR (Figure 25B), whereas the expression level of each transgene was analysed through WB 
(Figure 25A). Unfortunately, we noted that the C381A mutant was expressed at lower extent 
compared to WT; however, the I383A mutant displayed an expression level similar to WT, 
which allowed us to continue our analysis (Figure 25A, anti-HA WB). To uncover the role of 
these mutations in EGFR ubiquitination in vivo, we analysed EGFR ubiquitination in the 
different clones by WB upon stimulation with high dose of EGF (100 ng/ml) for 2 min. We 
observed that EGFR ubiquitination was impaired in the absence of c-Cbl, but expression of 
the WT protein reconstituted this defect (Figure 25C). On the contrary, both mutants did not 
rescue the defect of EGFR ubiquitination upon c-Cbl KD. This result shows that both c-Cbl 
mutants are indeed E3 ligase impaired also in vivo, confirming the in vitro data. 
 
 
Figure 25 E3 ligase activity of c-Cbl is required for EGFR CME in HeLa cells. (A) 
HeLa cells stably expressing different c-Cbl constructs were silenced for c-Cbl (+) or 
transfected with control oligos (-). Levels of c-Cbl (both silenced and overexpressed) were 
 113 
determined by immunoblotting using specific antibodies, as indicated. Note that with anti-
Cbl antibody we are detecting both endogenous c-Cbl and transgene, while with anti-HA 
we are detecting only the transgene. Tubulin was used as a protein loading control. (B) 
qPCR analysis to detect levels of c-Cbl KD of the sample used in (A). In order to follow 
only the  endogenous C-CBL we employed oligos targeting the 3’-UTR. Data were 
normalized on the housekeeping gene 18S and control sample was used as reference. Fold 
changes were reported. (C) In vivo EGFR ubiquitination. HeLa clones used in this study 
were serum starved o.n. (-) and then stimulated (+) with high dose of EGF (100 ng/ml) for 
2 minutes. EGFR was immunoprecipitated with anti-EGFR antibodies and ubiquitination 
was detected through a specific antibody against ubiquitin (P4D1, Santa Cruz). Levels of 
precipitated EGFR were determined with anti-EGFR antibodies. Results are representative 
of two experiments. (D) 125I-EGF internalization upon KD of Cbl proteins. EGF 
internalization was measured in the presence of 125I-EGF 1 ng/ml at initial time points (2, 4 
and 6 min). Internalization constants were extrapolated from the internalization curves and 
correspond to the slopes of the best-fitting curves. 
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7 The E3 ligase activity of c-Cbl is required for EGFR CME 
We then exploited this reconstitution system to investigate whether the E3 ligase activity of 
c-Cbl is required for EGFR CME by performing 125I-EGF internalization assays in the clones 
previously described upon c-Cbl KD. As shown in Figure 25D, upon c-Cbl KD, control cells 
displayed an internalization defect (about 30%) that was rescued in the c-Cbl WT expressing 
clone. On the contrary, both mutants were not able to reconstitute EGFR internalization 
defect upon c-Cbl KD. These data show that the E3 ligase activity of c-Cbl is required for 
EGFR CME.  
We further confirmed this hypothesis by taking advantage of NR6 cells expressing 
EGFR WT. In particular, we infected these cells with lentiviral inducible vectors expressing 
WT or mutant forms of c-Cbl (C381A and I383A). The homogenous expression of the 
inducible constructs was verified through WB, qPCR and IF analysis upon doxycycline 
treatment (Figure 26). All clones expressed c-Cbl WT and mutants at the same level.  
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Figure 26 Characterization of NR6 EGFR WT expressing either c-Cbl WT, C381A or 
I383A. (A) NR6 EGFR WT were infected with lentiviral vectors carrying c-Cbl WT, 
C381A and I383A and treated (+) with doxycycline 100 ng/ml o.n. Levels of c-Cbl 
induction were determined by immunoblotting using specific antibody, as indicated. 
Tubulin was used as a protein loading control. (B) qPCR analysis to determine mRNA 
levels of human C-CBL induction upon doxycycline treatment. Data were normalized on 
the housekeeping gene 18S. Fold changes are reported. (C) The homogeneity of the 
population was analyzed through IF analysis; human c-Cbl was detected through an 
antibody detecting the C-terminus of the protein. The primary antibody was revealed 
through anti-mouse Cy3 secondary antibody. 
 
We then performed 125I-ligand internalization assays at low EGF concentration with 
NR6 cells expressing c-Cbl WT, C381A and I383A, upon c-Cbl/Cbl-b KD. The expression 
level of each transgene and the ablation of endogenous c-Cbl were analysed through WB and 
qPCR analysis (Figure 27A, B). Since WB analysis does not allow to discriminate between 
endogenous and exogenous c-Cbl [the two proteins migrate at the same molecular weight 
(MW)], we analysed the expression levels of endogenous and exogenous c-Cbl through 
qPCR, by taking advantage of the fact that the inducible gene is human while the endogenous 
is mouse. We were able to reach the same KD level in all samples (Figure 27B, middle and 
lower panel). The overexpression of the different c-Cbl WT and mutants was similar upon 
doxycycline treatment (Figure 27B, upper panel). We observed that after c-Cbl/Cbl-b KD a 
slight reduction of transgene expression occurred, which, however, was the same in all 
samples. We then performed internalization assays at low EGF doses, in control and c-
Cbl/Cbl-b KD conditions, both in absence and in presence of doxycycline. The control (EV) 
was also treated with the doxycycline in order to exclude non-specific effects. As shown in 
Figure 27C, upon c-Cbl/Cbl-b KD, control cells displayed an internalization defect (about 
60%) that was rescued upon induction of c-Cbl WT expression. On the contrary, both 
mutants were not able to rescue the EGFR internalization defect upon c-Cbl/Cbl-b KD. Of 
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note, the two mutants also showed a dominant negative effect on EGFR internalization when 
overexpressed in the presence of the endogenous proteins (+ doxycycline, in absence of c-
Cbl/Cbl-b KD, Figure 27C). 
Taken together, our data suggest that mutations in the RING finger domain abolish 
the E3 ligase activity of c-Cbl; this activity is required for the early steps of EGFR CME. 
Since ubiquitination of the EGFR itself seems not to play a major role in CME, a possibility 
is that the E3 ligase activity may be required to ubiquitinate endocytic adaptors and not 
directly the EGFR.  
 
 
Figure 27 E3 ligase activity of c-Cbl is required for EGFR CME in NR6 EGFR WT 
cells. (A) NR6 cells infected with inducible constructs encoding for c-Cbl WT, C381A or 
I383A were silenced for c-Cbl and Cbl-b and treated with 100 ng/ml doxycycline o.n. 
Levels of c-Cbl were detected by immunoblotting using specific antibody, as indicated. 
Tubulin was used as a protein loading control. Note that we detected both endogenous and 
the c-Cbl transgene. (B) qPCR analysis to determine human C-CBL induction upon 
doxycycline treatment (upper panel), levels of endogenous c-Cbl (middle panel) and Cbl-b 
upon KD (lower panel). Data were normalized on the housekeeping gene 18S and fold 
change were reported. (C) Kinetics of 125I-EGF internalization at low EGF concentrations 
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(1 ng/ml) upon different KD were analysed at initial time points (4, 8 and 12 min). 
Internalization constants were extrapolated from the internalization curves and correspond 
to the slopes of the best-fitting curves. 
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8 Cbl proteins are involved in ubiquitination of the adaptor protein 
Eps15 
Several proteins are implicated in the initial steps of EGFR internalization and have been 
suggested to work as clathrin adaptors. Among these, Eps15, Eps15L1 and epsins might 
represent possible targets of c-Cbl E3 ligase since they are monoubiquitinated upon EGF at 
early time points (22). Importantly, we know that Eps15 is monoubiquitinated at similar level 
both at low EGF (only CME is active) and high EGF (CME and NCE are present), 
suggesting that Eps15 ubiquitination might play a role in EGFR CME (Figure 28A). 
 
 
Figure 28 Eps15 ubiquitination follows similar behaviour at low and high doses of 
EGF. HeLa cells were serum starved o.n. and then stimulated with different concentrations 
of EGF (1.5 or 100 ng/ml) for 2 minutes. (A) Eps15 ubiquitination in vivo. Eps15 was 
immunoprecipitated with specific antibodies and ubiquitination was detected using a 
specific antibody against ubiquitin (P4D1, Santa Cruz). The levels of Eps15 
immunoprecipitated were analysed by using specific antibodies. (B) EGFR ubiquitination 
in vivo as a control. EGFR was immunoprecipitated with anti-EGFR antibodies and 
ubiquitination was detected through a specific antibody against ubiquitin (P4D1, Santa 
Cruz). Levels of precipitated EGFR were determined with anti-EGFR antibodies.  
 
To test this hypotesis, we analysed Eps15 ubiquitination in c-Cbl KD cells compared 
to control cells by WB upon EGF stimulation at high dose (100 ng/ml) (Figure 29). At 2 
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minutes, control cells showed a peak of Eps15 ubiquitination that later decreased; on the 
other hand, c-Cbl KD cells showed a reduction in Eps15 ubiquitination. These data indicate a 
possible direct or indirect role for c-Cbl in Eps15 ubiquitination. It will be important to test 
whether this is true also for other components of the endocytic clathrin machinery. 
 
 
 
Figure 29 Eps15 as a possible substrate for c-Cbl in HeLa cells. Role of c-Cbl on Eps15 
ubiquitination in vivo. HeLa cells were transiently KD for c-Cbl or with a scramble as a 
control. These samples were serum starved o.n. (-) and stimulated with 100 ng/ml EGF at 
indicated time points. Eps15 was immunoprecipitated with specific antibodies and 
ubiquitination was detected through a specific antibody against ubiquitin (P4D1, Santa 
Cruz). The levels of Eps15 immunoprecipitated were analysed by using specific 
antibodies. Protein expression was determined as indicated. Actin was used as protein 
loading control. 
 
We further confirmed this result in NR6 EGFR WT cells expressing the inducible c-
Cbl WT. To this aim, we assessed whether c-Cbl and Cbl-b might play a role in Eps15 
ubiquitination and if c-Cbl WT could be able to rescue a possible ubiquitination defect. We 
silenced the two proteins simultaneously. c-Cbl expression (both in silencing and inducing 
conditions) was analysed through WB (Figure 30A) and qPCR analysis (Figure 30B). As 
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shown in the WB, upon doxycycline treatment, c-Cbl was greatly induced (lanes 2,4). The 
antibody used for Cbl-b IB recognizes both Cbl-b and c-Cbl (when overexpressed); indeed, 
as indicated in Figure 30A, the upper band corresponds to Cbl-b, while the lower one 
represents overexpressed c-Cbl. Importantly, upon c-Cbl/Cbl-b KD, the levels of Eps15, both 
protein and mRNA, increase (Figure 30A, B upper panel). In these cells, we investigated the 
Eps15 monoubiquitination by WB, thus we serum starved cells and then stimulated with high 
dose of EGF for 2 minutes. Lysates were subjected to Eps15 immunoprecipitation and then 
analysed by WB anti-Eps15; Eps15 ubiquitination levels were inferred from the shift in MW. 
As shown in Figure 30C, upon EGF stimulation cells showed a shift in Eps15 MW, 
corresponding to its ubiquitination, which decreased when Cbl proteins were ablated. Upon 
exogenous c-Cbl overexpression, we were able to fully rescue the defect of Eps15 
ubiquitination, suggesting that Eps15 might be a good candidate on which c-Cbl could exert 
its E3 ligase activity. c-Cbl might be involved in Eps15 ubiquitination either directly or 
indirectly (see discussion, section 5). 
 
 
Figure 30 c-Cbl is involved in Eps15 ubiquitination in NR6 cells. NR6 cells infected 
with lentiviral construct carrying c-Cbl WT were silenced for c-Cbl and Cbl-b and treated 
with 100 ng/ml doxycycline o.n. (A) Protein expression (both silencing and induction) was 
detected by immunoblotting using specific antibodies, as indicated. Tubulin was used as a 
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protein loading control. (B) qPCR analysis to determine either endogenous Eps15 levels 
(upper, left panel), endogenous c-Cbl (upper, right panel), endogenous Cbl-b (lower, left 
panel) and the transgene C-CBL (lower, right panel) upon c-Cbl/Cbl-b KD. Data were 
normalized on the housekeeping gene 18S and reported as fold change. (C) Eps15 
ubiquitination in vivo. Cells were serum starved 8 hours (-) and stimulated with 100 ng/ml 
EGF for two minutes. Eps15 was immunoprecipitated and analysed with specific antibody. 
 
To investigate whether c-Cbl is involved in Eps15 ubiquitination through a direct or 
indirect mechanism, we performed an in vitro ubiquitination assay, by using c-Cbl as E3 
ligase and Eps15 as substrate. Since it is known that activation of c-Cbl requires 
phosphorylation, we used both unphosphorylated and phosphorylated (by purified EGFR 
kinase) forms of c-Cbl to perform this assay. As shown in Figure 31, only the active form of 
c-Cbl was able to ubiquitinate the adaptor protein Eps15. This result suggests that active c-
Cbl may in principle directly act as E3 ligase on Eps15. However, since in vitro assays can 
be quite unspecific, further experiments are needed to gain a better understanding of c-Cbl 
E3 ligase activity. In particular, it would be interesting to investigate if Eps15 is a direct 
target of c-Cbl, whether c-Cbl can ubiquitinate also other endocytic adaptors and if and how 
ubiquitination of these adaptor proteins is indeed involved in EGFR CME. 
 
 
Figure 31 Role of c-Cbl on Eps15 ubiquitination in vitro. In vitro phosphorylated (pY-c-
Cbl) or unphosphorylated c-Cbl (c-Cbl) were used as E3 ligase to perform in vitro 
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ubiquitination reactions that imply incubation of the substrate GST-Eps15 with ubiquitin (1 
ug), bacterially purified E1 (100 ng), UbcH5c as E2 (500 ng), E3 (500 ng) and ATP 
regeneration system. Results from the control reaction without E2 are shown. 
Immunoblotting was performed with the indicated antibodies. Results are representative of 
two experiments. 
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Appendix 
1 The contribution of c-Cbl and Cbl-b as EGFR regulators might rely 
on their relative abundance in the cells 
We would like to underline that the role of Cbl proteins as EGFR regulators is cell context-
dependent. Indeed, while in NR6 cells, c-Cbl and Cbl-b seem to play redundant roles in the 
early steps of EGFR CME (Figure 22D), in HeLa cells, c-Cbl is the major player involved 
in this endocytic pathway (Figure 20B).  
To confirm these results, we analysed another cell line, such as another HeLa cell 
clone (named HeLa-Oslo) exhibiting different expression levels of the two proteins. HeLa-
Oslo cells are a clone of HeLa cells, charaterized for the absence of the NCE (226,233). 
HeLa-Oslo cells show similar levels of the mRNA of the C-CBL and CBL-B genes, 
displaying only a lower expression of CBL-B compared to C-CBL [about 15% (Figure 
32)], as observed in NR6 cells. 
 
 
Figure 32 Comparison of C-CBL and CBL-B expression in HeLa (HeLa-Milan) vs 
HeLa-Oslo cells. Levels of C-CBL, CBL-B and CBL-C were analysed through qPCR 
analysis. On the left panel Ct values are reported. The mRNA levels of the different genes 
were normalized to the housekeeping gene 18S. Fold changes are reported. 
 
We characterized this HeLa-Oslo line for the impact of Cbl proteins in EGFR CME 
and ubiquitination. As previously described, using an RNAi-based approach [single or 
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double KD (Figure 33A)], we observed that, like in NR6 cells, EGFR clathrin-mediated 
internalization is only slightly reduced upon single KD, while it is strongly impaired when 
both the proteins were silenced (Figure 33B). Also EGFR ubiquitination was affected at 
the same extent, thus only when the two members were KD (Figure 33C), suggesting a 
redundant role of c-Cbl and Cbl-b both in EGFR CME and its ubiquitination. 
 
 
Figure 33 Cbl proteins play redundant roles in EGFR CME and ubiquitination in 
HeLa-Oslo. (A) HeLa-Oslo cells were silenced for c-Cbl and Cbl-b. Expression levels 
were determined by immunoblotting using specific antibodies, as indicated. (B) 125I-EGF 
internalization in Hela-Oslo cells, upon KD of Cbl proteins. EGF internalization was 
measured in the presence of 125I-EGF 1 ng/ml at initial time points (2, 4 and 6 min). 
Internalization constants were extrapolated from the internalization curves and correspond 
to the slopes of the best-fitting curves.  (C) In vivo EGFR ubiquitination. HeLa-Oslo cells, 
subjected to KD as indicated, were serum starved o.n. (-) and then stimulated (+) with high 
dose of EGF (100 ng/ml) for 2 minutes. EGFR was immunoprecipitated with anti-EGFR 
antibodies and ubiquitination was detected through a specific antibody against ubiquitin 
(P4D1, Santa Cruz). Levels of immunoprecipitated EGFR were determined with anti-
EGFR antibodies.  
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One possible explanation for the differential role of c-Cbl/Cbl-b in HeLa (Milan) 
versus NR6 cells  (or HeLa-Oslo) might rely on the different levels of expression observed 
in HeLa and NR6 cells (or HeLa-Oslo). However, other scenarios might explain this 
difference. Indeed, it is possible that a differential regulation/localization of the two ligases 
occurs in the analysed cell lines. We will investigate this possibility in future studies. 
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2 Role of c-Cbl vs Cbl-b in EGFR degradation  
EGFR ubiquitination is known to play an important role in signal extinction, by targeting 
the receptor to lysosomal degradation.  We investigated if the observed effects on EGFR 
ubiquitination could correlate with a concomitant delay in EGFR degradation and whether 
c-Cbl and/or Cbl-b could play different roles in EGFR degradation in HeLa cells. To this 
aim, after stimulation with a high dose of ligand (100 ng/ml of EGF), we assessed the 
degradation of the receptor by WB (Figure 34B, C). In single KD (c-Cbl and Cbl-b), we 
did not score any defect in EGFR degradation, while a significant delay was evident in c-
Cbl/Cbl-b double KD. This result suggests that Cbl-b might play a specific role at later 
stages of EGFR endocytosis, redundantly with c-Cbl. 
 
 
Figure 34 Role of Cbl proteins in EGFR  degradation. (A) HeLa cells were silenced for 
c-Cbl and Cbl-b (single or in combination). Expression levels of Cbl proteins were 
determined by immunoblotting using specific antibodies, as indicated. Tubulin was used as 
protein loading control. (B) Analysis of EGFR degradation. Upon the indicated KDs, cells 
were stimulated with high dose of EGF (100 ng/ml) at different time points after an o.n. 
serum deprivation. EGFR levels were evaluated through WB as indicated. Tubulin was 
used as a protein loading control. (C) Quantification of EGFR levels shown in (B) through 
Photoshop analysis. 
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An important issue arising from our data is the uncoupling between the major role 
of c-Cbl in EGFR ubiquitination and its mild effect on EGFR degradation. A first, easy, 
explanation might be that the residual ubiquitination in c-Cbl KD cells is sufficient to 
target the receptor to the degradative lysosomal pathway. Only by further reducing 
ubiquitination through Cbl-b KD were we able to block EGFR degradation. Another 
possibility might be that c-Cbl and Cbl-b are able to generate different types of ubiquitin 
signals on the EGFR with distinct role along the endocytic pathway. Indeed, it is known 
that the EGFR can be modified either by multiple monoubiquitination or by short K63-
linked chains in the kinase domain (148), although the role of these two modifications is 
still unclear. By using EGFR-ERBB4 chimeras, it has been recently demonstrated that c-
Cbl is responsible for K48-polyubiquitination upon ligand stimulation (246). In the future, 
we plan to investigate this issue by performing in vitro ubiquitination assays using 
ubiquitin mutants in which the lysines are mutated into Arg. These mutations do not allow 
the formation of the corresponding Ub chains and let us discriminate the specificity of the 
E3 ligase activity. 
A more complex hypothesis explaining the observed c-Cbl phenotype would be 
that another mechanism of EGFR degradation exists and is independent of direct receptor-
ubiquitination. For instance, Cbl-b might influence EGFR degradation by ubiquitinating 
endocytic adaptors involved at a later endocytic stage. Indeed, at this step, different 
adaptors have been shown to be ubiquitinated, such as Hrs (130), STAM or Eps15b 
[reviewed in (147)]. However, these are pure speculations and further studies will be 
required to clarify this point. 
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Discussion 
1 Role of c-Cbl in EGFR CME  
Ubiquitination was first implicated in yeast endocytosis. In this model system, ubiquitin 
modifications are both necessary and sufficient for the internalization of many plasma 
membrane proteins (114,125). In mammalian cells, the situation is less clear, since for 
many endocytic cargoes (such as RTKs and GPCRs), ubiquitination appears to be 
sufficient but not required for internalization (1,2), while for other proteins, such as ion 
channels, ubiquitination is an essential step of the endocytic trafficking (125). These 
findings are indicative of the presence of multiple, redundant but distinct mechanisms of 
endocytosis that may depend on ubiquitination or not (128). In the case of the EGFR, these 
mechanisms include ubiquitination of Lys residues in the intracellular kinase domain of the 
receptor, interaction of the receptor with the AP2 complex and with the adaptor protein 
Grb2, and acetylation of C-terminal Lys residues (128). Likely, the relative contribution of 
these mechanisms varies depending on the cell type taken into consideration and 
experimental conditions adopted, that not all mechanisms are simultaneously employed by 
a single cell and that some mechanisms are preferentially engaged under physiological 
conditions.  
Moreover, we should consider that some studies have shown that EGFR 
ubiquitination is detectable even at low EGF concentrations, and that ubiquitination can 
promote the translocation of the receptors to clathrin-coated pits (79). Thus, the 
contribution of ubiquitination to EGFR CME still remains somewhat elusive and can be 
influenced by the experimental conditions used (1,2,79,128). Moreover, not only the 
receptor but also the endocytic adaptors are often ubiquitinated in response to extracellular 
stimuli (22).  
For EGFR, at least two distinct internalization pathways have been described: CME 
and NCE. The molecular machinery involved in NCE is still poorly defined. Despite this, 
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we have shown in the past (and confirmed in the present work) that ubiquitination of the 
EGFR is absolutely essential for EGFR internalization through this pathway. Contrary to 
NCE, CME is very well characterized at the molecular level. Several groups, including our 
own, have relied on different tools and approaches to investigate the role of EGFR 
ubiquitination in CME (1,2). However, if and how EGFR ubiquitination is required at the 
initial steps of the process is still debated. Thus, one of the goals of this work was to clarify 
the role of EGFR ubiquitination in CME.  
To this aim, we undertook a genetic approach through the generation of an EGFR 
mutant lacking c-Cbl-binding sites. Importantly, our mutant (3F) was negative for EGFR 
ubiquitination (as assessed by WB analysis, Figure 22C) and was unable to recruit c-Cbl 
(Figure 22E). On the contrary, Grb2 binding was only partially impaired (Figure 22E). 
This observation might be explained by the fact that Grb2 also interacts with the EGFR 
through the adaptor protein Shc, which upon EGF stimulation binds the pY1173 of the 
cytoplasmic tail of the receptor and undergoes phosphorylation and activation. Despite this 
fact, it is clear from our results that either c-Cbl recruitment to the 3F mutant is severely 
impaired or a labile interaction between c-Cbl and the EGFR is formed. Therefore, this 
mutant represents a powerful tool to analyse the involvement of c-Cbl in EGFR 
internalization regardless of its stable recruitment to EGFR. We addressed this issue and 
observed that internalization of the Ub negative mutant 3F was still dependent on c-Cbl 
and Cbl-b (Figure 22D). This result suggests that the role of Cbl proteins in EGFR CME is 
independent of their ability to ubiquitinate the receptor. These results are in agreement 
with the body of knowledge that indicates that c-Cbl is directly involved in CME through 
its role as an adaptor or as an E3 ligase for proteins different from the EGFR (3,97). 
Indeed, we predict that Cbl proteins exert their role in CME possibly through 
ubiquitination of other substrates required for this process. The ubiquitination of other 
substrates by c-Cbl may be completely independent on the direct recruitment of c-Cbl to 
the EGFR or may simply result from a transient interaction of c-Cbl with EGFR, which 
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would allow the ubiquitin ligase to exert its function on endocytic adaptors. However, it is 
also possible that c-Cbl works in parallel as adaptor and as E3 ligase, an issue that wants 
further investigations in the future through the use of mutants, e.g. the mutations that have 
been mostly shown to be found in tumors (see section 4). 
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2 Interplay between c-Cbl and Grb2 in EGFR ubiquitination and 
internalization. 
c-Cbl is recruited to the activated EGFR both directly, by binding to the pY1045 and 
indirectly, through the adaptor protein Grb2, which binds to the pY1068/1086 (Figure 17A). 
We have demonstrated that the efficient recruitment of c-Cbl to the receptor leads to a 
massive ubiquitination of the EGFR both in vitro (Figure 17B) and in vivo (226). Initially, 
this interplay between c-Cbl and Grb2 was investigated using chimera constructs. Indeed, 
upon EGF stimulation, c-Cbl-yellow fluorescent protein (YFP) translocated with the EGFR 
to clathrin-coated pits and endosomes and this localization was dependent on the interaction 
between the proline-rich region of c-Cbl and the SH3 domain of Grb2 (234). On the contrary, 
direct binding of c-Cbl to pY1045 of the EGFR was required for its ubiquitination, but was 
not essential for c-Cbl-YFP localization in EGFR-containing compartments. These data 
suggest that the binding of c-Cbl to the activated receptor through Grb2 is necessary and 
sufficient for c-Cbl function during clathrin-mediated endocytosis (234). We confirmed these 
data, by demonstrating that while c-Cbl KD induces a partial decrease in EGFR CME 
(Figure 18B, left panel), Grb2 plays an essential role in EGFR clathrin-mediated 
internalization (Figure 19B, left panel). We were also able to establish that both c-Cbl and 
Grb2 are critical players in EGFR NCE (Figure 18B and Figure 19B right panel). 
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3 c-Cbl versus Cbl-b  
The role of c-Cbl as adaptor in EGFR endocytosis is well characterized. We wondered 
whether the other member of the Cbl family expressed in HeLa and NR6 cells - Cbl-b - could 
have a similar impact on EGFR internalization in our cellular systems. However, we found 
that these two Cbl proteins behave differently in the two cellular models studies. Indeed, in 
HeLa cells, Cbl-b does not seem to be involved in the early steps of EGFR internalization, 
both clathrin-mediated and clathrin-independent (Figure 20B left and right panel, 
respectively). On the contrary, in NR6 cells, these two proteins seem to play redundant roles 
in EGFR CME (Figure 22D). Of note, in HeLa-Oslo cells, which show similar expression 
levels of c-Cbl and Cbl-b as NR6 cells, the redundant behaviour of c-Cbl and Cbl-b in EGFR 
CME was confirmed (Figure 33B). In addition, our results also show that the roles of c-Cbl 
and Cbl-b in EGFR ubiquitination are also cell-context dependent. Indeed, while in HeLa 
cells, c-Cbl is the major E3 ligase involved in EGFR ubiquitination (Figure 16C), in NR6 
cells (Figure 22C) and HeLa-Oslo cells (Figure 33C) the two Cbl E3 ligases act redundantly. 
These discrepant behaviours might be explained by the different expression level of the two 
genes and consequently of the corresponding proteins (Figure 16A, Figure 22A and Figure 
32). 
 Another difference between c-Cbl and Cbl-b roles in EGFR ubiquitination was 
observed in HeLa cells. Indeed, we demonstrated that c-Cbl plays the most predominant role 
in ubiquitinating the EGFR both at the plasma membrane (Figure 16C) and all along the 
endocytic route (Figure 16D). However, even though c-Cbl has been characterized as the 
major E3 ligase of the EGFR in HeLa cells, when we analysed the degradation of the 
receptor, we noticed an uncoupling of the role of c-Cbl in EGFR ubiquitination and 
degradation. Indeed, when c-Cbl and Cbl-b were singularly KD, no defects in EGFR 
degradation were observed along the kinetics studied (Figure 34B, C). On the contrary, in the 
presence of double KD, EGFR degradation was delayed, suggesting that either the minimal 
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ubiquitination present in c-Cbl KD cells is sufficient to target the receptor to degradation, or 
that c-Cbl and Cbl-b may generate different types of Ub signals on the EGFR with distinct 
role along the endocytic pathway, or that the EGFR degradation is independent on its 
ubiquitination (see appendix, section 2). 
 A possible explanation for the different impact of c-Cbl and Cbl-b on EGFR 
internalization and ubiquitination may reside in the structure of these two proteins, namely 
in the UBA domain at their C-terminus. Importantly, although both c-Cbl and Cbl-b have a 
UBA domain at their C-terminal, only the UBA domain of Cbl-b has been demonstrated to 
bind ubiquitin (or ubiquitinated proteins) (165). Indeed, in vitro, the UBA domain of Cbl-
b, and not of c-Cbl, can interact with ubiquitinated proteins and Ub chains, showing a 
greater affinity for polyubiquitin chains compared to monoubiquitin. The affinity for 
ubiquitin resides in differences in several aminoacids between the domains of the two 
proteins. Thus, this constrasting ability in ubiquitin-binding may reflect distinct regulatory 
functions of c-Cbl and Cbl-b. Moreover, a study using site-directed mutagenesis has 
demonstrated that Cbl-b dimerization is regulated by Ub binding and is required for its 
tyrosine phosphorylation and consequent E3 ligase activity on the substrates (247). 
 Importantly, another difference between these two proteins can be observed in 
cancer. Indeed, while several studies have reported c-Cbl mutations located in the linker 
region and RING finger domain in myeloid neoplasm [see introduction, chapter 5.5 and 
(226)], only two studies have described frame shift or missense mutations within the RING 
finger domain of Cbl-b (194,198), suggesting that the frequency of Cbl-b mutations in 
myeloid neoplasm is lower compared to c-Cbl (193,196). Moreover, c-Cbl-/- and Cbl-b-/- 
mice display distinct phenotypes, in particular concerning the alteration of signalling 
pathways in thymocytes or mature T cells (see introduction, chapter 5.4). This may reflect 
differences in the expression of the two proteins between thymocytes and peripheral T 
cells.
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4 E3 ligase versus adaptor function 
It is widely described that c-Cbl can interact with several proteins involved in CME (3). 
Indeed, by functioning as adaptor, c-Cbl can recruit the adaptor molecules CIN85 and 
CD2AP (127), which trigger signalling cascades that initiate early phases of receptor 
endocytosis. 
 
Figure 35 c-Cbl interacts with multiple proteins of CME. Following EGF stimulation, 
EGFR-associated proteins of the c-Cbl interactome, as c-Cbl itself, clathrin and dynamin,  
become phosphorylated by Src. This is an essential step for the onset of endocytosis. In 
parallel, PLC is activated and produces the second-messenger molecules diacylglycerol 
(DAG) and inositol trisphosphate (InsP3). This results in an increase of intracellular Ca2+ 
concentrations, activation of PKC and initial negative regulation of c-Cbl through 
phosphorylation of serine residues. At the same time, the Ras pathway is activated through 
Grb2 and SOS (son-of-sevenless), and this stimulates the MAPK cascade (3). 
 
In order to dissect its role as E3 ligase versus adaptor function in EGFR CME, we 
generated mutants in the RING finger domain (C381A and I383A) and showed that such 
mutants display abrogated E3 ligase activity in an in vitro ubiquitination assay (Figure 
23B). Yet, these two mutants did not display the same behaviour in an overexpression 
system; indeed, while expression of c-Cbl C381A mutant induced complete EGFR 
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ubiquitination impairment, expression of c-Cbl I383A mutant affected receptor 
ubiquitination to a lesser extent (Figure 23C, D). This may be explained by the fact that 
only the cysteine mutation can completely disrupt the structure of the RING (245). Since c-
Cbl can homo- and hetero-dimerize with Cbl-b, when overexpressed this mutant may 
interact with the endogenous proteins leading to their instability and inhibiting their action. 
On the contrary, the mutation I383A has been described to prevent the interaction with the 
E2, leaving intact the RING finger domain. These differences might explain the dominant 
negative effect exerted by the C381A mutant compared to the I383A. Indeed, in 
ubiquitination reconstitution experiments, upon c-Cbl and Cbl-b KD, both the RING finger 
mutants displayed the same ubiquitination defect, as they were not able to rescue the 
ubiquitination defect, differently from the WT protein (Figure 25C). In this case, upon 
silencing of the endogenous proteins, we cannot discriminate a dominant negative 
behaviour of the mutants. 
Thus, we demonstrated that these mutations affected E3 ligase activity both in vivo 
and in vitro and represented a powerful tool to dissect a possible role of c-Cbl as E3 ligase 
in EGFR CME. To this aim, we exploited this system in two cellular contexts (HeLa cells 
and NR6 cells), by performing reconstitution assays of 125I-EGF internalization. In both 
cases, we demonstrated that c-Cbl E3 ligase activity is required for EGFR CME, since both 
mutants were not able to reconstitute the defect of EGFR internalization upon Cbl proteins 
KD (Figure 25D, Figure 26C). Moreover, in an overexpression system both C381A and 
I383A behaved as dominant negative mutants, by decreasing EGFR internalization 
compared to the untreated samples (Figure 26C). Therefore we can conclude that c-Cbl is 
involved in EGFR internalization by acting as E3 ligase, an activity that is not exerted on 
the receptor but possibly on endocytic adaptors involved in CME. 
In order to dissect c-Cbl adaptor function vs E3 ligase activity, we additionally 
undertook a bioinformatic approach, through which we analysed the hotspot mutations 
present in c-Cbl in the different types of tumors, by taking advantage of the bioinformatic 
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portal cBio and TCGA (The Cancer Genome Atlas) as source of data. In the Table 5 we 
represented the most frequent mutations that occur in C-CBL gene as well as the frequency 
of occurency. 
 
 
Table 5 Hotspot mutations in c-Cbl. Through a bioinformatic analysis using TCGA as 
source of data, we found the residues shown in the table, mutated in different types of 
cancer (breast, lung adenocarcinoma, lung squamous cell carcinoma, rectum and colon 
adenocarcinoma, uterine corpus endometrioid carcinoma). The original aminoacid, its 
conversion and the position in the sequence are represented. The position within the 
structure and the frequency of occurrency considering all the mutations (w/o the silent 
mutations) are depicted. The color code of the domains is related to the structure of c-Cbl 
depicted in Figure 14. 
 
gene original aa mutated aa position aa region frequency
c-CBL E K 276 TKB (SH2 domain) 3.10%
c-CBL E K 276 TKB (SH2 domain)
c-CBL K E 287 TKB (SH2 domain) 3.10%
c-CBL K R 287 TKB (SH2 domain)
c-CBL L S 338 TKB (SH2 domain) 3.10%
c-CBL L S 338 TKB (SH2 domain)
c-CBL Q STOP 367 LINKER 3.10%
c-CBL Q L 367 LINKER
c-CBL C R 381 RING 6.25%
c-CBL C G 381 RING
c-CBL C Y 381 RING
c-CBL C Y 381 RING
c-CBL P S 395 RING 3.10%
c-CBL P L 395 RING
c-CBL M T 400 RING 3.10%
c-CBL M T 400 RING
c-CBL C R 401 RING 4.70%
c-CBL C R 401 RING
c-CBL C F 401 RING
c-CBL R STOP 420 RING 4.70%
c-CBL R STOP 420 RING
c-CBL R Q 420 RING
c-CBL W R 802 3.10%
c-CBL W STOP 802
c-CBL G E 868 UBA 3.10%
c-CBL G V 868 UBA
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From this analysis we importantly scored the presence of several nonsense 
mutations (STOP codon). We investigated deeper and we found that the nonsense 
mutations are spread all along the sequence of the protein (Table 6). 
 
 
 
 
 
 
 
Table 6 Nonsense mutations in c-Cbl. Bioinformatic analysis using TCGA as source of 
data (same as Table 5) 
 
Data from literature have described the mutation c-Cbl W802* by analysing 119 
lung cancer patient tumor tissues (204). In an overexpression system, the mutation shows 
an intact E3 ligase activity on the activated EGFR, results in increased number of viable 
cells and leads to an increase in cell motility compared to the WT construct. However 
these studies were performed in presence of the endogenous Cbl proteins, thus 
investigating for a dominant negative effect of the mutation.  
In order to assess whether these mutations could be a useful tool to dissect the E3 
ligase activity vs the adaptor function, we firstly investigated whether the E3 ligase activity 
was impaired in an in vitro ubiquitination assay (Figure 36), but for the mutation c-Cbl 
W802* this was not the case. 
 
gene original aa mutated aa position aa region
c-CBL Q STOP 367 LINKER
c-CBL R STOP 420 RING
c-CBL R STOP 420 RING
c-CBL W STOP 802
c-CBL E STOP 894 UBA
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Figure 36 c-Cbl W802* is able to ubiquitinate EGFR in vitro. EGFR ubiquitination in 
vitro. GST-EGFR cytoplasmic tail was subjected to in vitro autophosphorylation reaction. 
Then, it was subjected to ubiquitination reaction in the presence of ubiquitin, bacterially 
purified E1, UbcH5c as E2, c-Cbl WT or c-Cbl W802* as E3, ATP regeneration system, 
with or without Grb2 (ten times c-Cbl in molarity). The control reactions with EGFR not 
phosphorylated or without E2 or E3 are shown. 
 
This result goes in the same direction with the findings that only in Cbl-b – and not 
in c-Cbl – the UBA domain is required for E3 ligase activity on substrates (247).  
An in-depth study and characterization of these mutations for EGFR internalization 
and ubiquitination, exploiting both in vivo analyses (reconstitution experiments in cell 
lines) and in vitro ubiquitination assays, will be helpful to possibly dissect the role of c-Cbl 
as E3 ligase and adaptor. 
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5 Role of Cbl proteins on Eps15 
Ub-mediated internalization or sorting of membrane receptors requires accurate recognition 
of the ubiquitinated cargo by endocytic Ub receptors, which are proteins that contain UBDs. 
These endocytic adaptors have the ability to interact with both ubiquitinated cargoes and 
components of the endocytic machinery. Among these adaptors, Epsins, Eps15 and Eps15L1 
are the ones that were shown to recognize ubiquitinated EGFR at the early steps of 
endocytosis; their cargo selectivity comes from tandemly arrayed Ub-interacting motifs (1). 
Due to their overlapping binding abilities, these adaptors seem to play redundant roles (1). 
Indeed, although Eps15, Eps15L1and Epsins have all been traditionally linked to CME 
(248), they are absolutely required also for clathrin-independent endocytosis of the EGF 
receptor (1). Importantly, this latter function is exerted through the binding of adaptor UIMs 
to the ubiquitinated EGFR (1). These proteins are also modified themselves by 
monoubiquitination upon EGFR activation (22,127,130,131). The presence of a UBD is 
required for monoubiquitination of the UBD-harbouring adaptor, in a process called 
“coupled monoubiquitination”. This process has been elucidated using Eps15s and Epsins as 
model systems (22,249). The HECT E3 ligase Nedd4 has been involved in their 
ubiquitination (249). Moreover, we have also shown here that Eps15 undergoes 
monoubiquitination at the same extent both at low and high dose of EGF (Figure 28). 
However, the molecular mechanism by which the upstream signal induced by the activated 
EGFR causes Nedd4 engagement still needs to be clarified.  
This still open scenario led us to better investigate the molecular mechanism 
underneath the EGFR CME, by focusing on a possible relation c-Cbl/Eps15. Both RNA 
interference experiments performed in vivo [in HeLa and NR6 cells (Figure 29, Figure 30)] 
and in vitro (Figure 31), suggest that c-Cbl may indeed regulate Eps15 
monoubiquitination, through a direct or indirect mechanism. In the latter case, since Eps15 
can be monoubiquitinated by members of the Nedd4 family of E3 ligases, whose activity is 
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also regulated by ubiquitination (249), we may hypothesize a circuitry in which Cbl 
proteins can regulate Nedd4 E3 ligase activity on Eps15. Bidirectional interplay between 
Nedd4 family and Cbl family have been described in the past. For instance, Nedd4 and Itch 
bind and ubiquitinate all the mammalian Cbl proteins targeting them to lysosomal 
degradation. Consistent with this, Nedd4 prevents c-Cbl-mediated EGFR ubiquitination 
and downregulation and results in a persistent downstream signalling by EGFR (181). 
Regulation of Nedd4 by Cbl family members are also described: recent studies have 
differently shed light on the circuitry involving Nedd4 and Cbl proteins in different cell 
systems (T cells), where loss of Cbl-b enhanced Nedd4 ubiquitination that did not result in 
its degradation, while the presence of Cbl-b inhibited Nedd4 E3 ligase activity in vitro 
(250). However this type of regulation is apparently in the opposite direction of the simple 
model that would explain our data, namely that c-Cbl positively regulates Nedd4 activity 
via ubiquitination. 
Another possibility is that c-Cbl directly ubiquitinates Eps15, a scenario that would 
be compatible with our in vitro ubiquitination assay. In this case, a possible scenario would 
be that the two different E3 ligases (c-Cbl and Nedd4) might play a role at different steps 
of the endocytic route of the EGFR. Indeed, Eps15 is recruited to the plasma membrane 
upon EGF stimulation and localizes to the coated pits (251). Recently, it has been 
demonstrated that Eps15b, an isoform of Eps15, is endosomally localized and directly 
interacts with Hrs (147). Interestingly, c-Cbl binds to the EGFR at the plasma membrane 
and remains associated to the ubiquitinated receptor throughout the endocytic route from 
the plasma membrane to late endosomes (136) and might be involved at early and late 
steps in combination with other E3 ligases, e.g. Nedd4 family. All these hypotheses will 
require further investigations in the future.  
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6 Role of Eps15 and other adaptors monoubiquitination in EGFR 
internalization 
The delivery of membrane receptors to the lysosome requires appropriate recognition of 
the ubiquitinated cargo by endosomal adaptors and sorting proteins. For the EGFR, for 
example, Eps15 and epsins act at the initial steps of internalization, serving to recruit the 
enzymes required for ubiquitination of downstream components of the endocytic pathway. 
On the contrary, ESCRTs act sequentially at various points of the degradative route, 
sorting the ubiquitinated cargo at the endosomal membrane for inclusion into the 
intraluminal vesicle of the MVB. ESCRT-0, composed of the two interacting proteins HRS 
and STAM, is the first ESCRT complex involved in this process. Three additional 
complexes, ESCRT-I, ESCRTII and ESCRT-III, then generate the inward vesicle budding, 
required for MVB maturation (78). These ubiquitin-binding ‘route controllers’ that ferry 
the internalized receptor towards a degradative fate into lysosomes are also inducibly 
ubiquitinated (22,130). 
The inducibility of the system illustrates the dynamic nature of EGFR endocytosis 
regulation based on ubiquitin. Indeed, over the past 15 years, several laboratories have 
shown a critical role for ubiquitination in receptor down-regulation, a process that is 
essential for the spatial and temporal resolution of receptor signalling (135). Moreover, we 
cannot exclude a possible involvement of other endocytic adaptors, such as CIN85, whose 
interaction with c-Cbl is known to increase upon RTK activation and RTK-induced 
phosphorylation of c-Cbl (127), even though the mechanism underlying this process is not 
clear. 
But what is the functional role of monoubiquitination of endocytic proteins? Two 
major hypotheses are most plausible. On the one hand, coupled monoubiquitination would 
increase the range of intermolecular interactions of the Ub receptor, creating a network of 
ubiquitin-based interactions, leading to signal amplification and progression of ubiquitinated 
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cargoes along the endocytic route (110,129). On the other hand, intramolecular interactions 
between monoUb and UBDs within the endocytic adaptor may lead to an autoinhibitory 
mechanism, which causes the dissociation of the Ub receptor from the ubiquitinated cargo 
(e.g., Sts2 and ubiquitinated EGFR) (132). Since these two possibilities are not mutually 
exclusive, both mechanisms could be involved in the regulation of endocytic processes, 
possibly by acting at distinct trafficking steps and/or regulating different endocytic adaptors. 
However, these are pure speculations. 
Preliminary data from our lab have demonstrated that an Eps15 mutant in which the 
six lysines in the UIM are mutated in arginines (6KR mutant) is not able to reconstitute the 
defect of EGFR internalization upon Eps15/Eps15L1/Epsin1 KD, suggesting the crucial 
importance of Eps15 monoubiquitination in EGFR endocytosis. 
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7 c-Cbl in cancer 
Interestingly, c-Cbl has been found mutated in human pathologies such NSCLC and 
myeloproliferative diseases (193); this may lead to dysregulation of RTKs (252). The 
absence of leukemia in c-Cbl knockout mice and its development in mice with a c-Cbl 
RING finger mutant knockin are explained by a dominant negative function of the mutant 
protein. However, the positive functions of Cbl proteins in signalling based on the adaptor 
function of c-Cbl suggest that the mutations may give rise to both a loss of tumor 
suppressor function and a gain of oncogene function. 
c-Cbl mutations occur throughout all the coding sequence (Figure 37), and are 
mostly located within the RING finger domain and in the regulatory linker region, 
therefore are predicted to involve both the ubiquitin ligase activity and protein-protein 
interactions. However some mutations map outside this region, suggesting that they might 
impinge on the adaptor function without altering the E3 ligase activity. None of these 
mutations has been characterized in detail at the mechanistic level.  
 
 
 
Figure 37 Mutations of c-Cbl in NSCLC and myeloproliferative diseases. At the 
bottom of the panel, a schematic representation of c-Cbl is shown with its functional 
domains. The ruler underneath shows aminoacids positions. The position and the 
frequency of the mutations detected in myeloproliferative diseases are shown by black 
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circles, while the ones detected in NSCLC are shown by red circles and are aligned with 
the aminoacid sequence [adapted from (4)]. 
 
While c-Cbl WT may work as onco-suppressor, mutants of c-Cbl can function as 
gain-of-function oncogenes. Since the mutations identified in the different leukemia are 
located in the RING finger and do not alter the TKB and C-terminal domain, interactions 
with a variety of signalling proteins are not affected. Thus, it is logical to hypothesize that 
these E3-ligase impaired proteins will be recruited to activated RTKs and that this will lead 
to the formation of a signalling complex that lacks the negative regulatory function of the 
c-Cbl WT. Thus, mutant c-Cbl proteins are likely to function as supramolecular scaffolds 
to assemble aberrant signalling complexes that can promote hyperactivation of signalling 
pathways normally attenuated by the WT counterpart. This hypothesis is compatible with 
analyses of a mutant c-Cbl knock-in mouse model developed by Langdon and colleagues. 
This model carries a c-Cbl RING finger mutant (C379A, corresponding to C381 in 
human), which is expressed under the control of the endogenous c-Cbl promoter (253). 
While homozygous mutant mice show early lethality, heterozygous mutant mice with one 
WT c-Cbl allele do not show hematopoietic abnormalities. However, mice with one 
C379A mutant allele in a c-Cbl-null background, but with intact Cbl-b, dispaly myeloid 
malignancies (200). Interestingly, Akt was constitutively activated in the C379A mutant 
hematopoietic cells but not in control or Cbl-null mutant cells (200). This went with 
enhanced phosphorylation of Y737 (corresponding to Y731 in human) of c-Cbl binding 
site for the p85 regulatory subunit of PI3K.  
These findings in mice carrying the RING finger mutant Cbl knock-in (200) 
suggest that wild type c-Cbl may act as tumor suppressor, while mutant c-Cbl might have 
oncogene functions. 
Further experiments are needed to better elucidate the molecular mechanism 
underlying the role of c-Cbl mutations in cancer development. 
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